ADMA Biologics Inc
Buy, Hold or Sell?

Let's analyse ADMA Biologics Inc together

Penke I guess you are interested in ADMA Biologics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ADMA Biologics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about ADMA Biologics Inc

I send you an email if I find something interesting about ADMA Biologics Inc.

Quick analysis of ADMA Biologics Inc (30 sec.)

What can you expect buying and holding a share of ADMA Biologics Inc? (30 sec.)

How much money do you get?

$0.00

When do you have the money?

1 year

How often do you get paid?

5.0%

What is your share worth?

Current worth

$0.59

Expected worth in 1 year

$0.52

How sure are you?

32.5%

+ What do you gain per year?

Total Gains per Share

$-0.07

Return On Investment

-1.1%

For what price can you sell your share?

Current Price per Share

$6.46

Expected price per share

$5.1 - $6.76

How sure are you?

50%

1. Valuation of ADMA Biologics Inc (5 min.)

Live pricePrice per Share (EOD)

$6.46

Book Value per Share

$0.59

Intrinsic Value Per Share

$-0.98 - $10.72

Total Value Per Share

$-0.39 - $11.32

My calculation of the intrinsic value of ADMA Biologics Inc is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($-0.06) 3Y: ($-0.07) TTM: ($0.00)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($0.00) 3Y: ($0.02) TTM: ($0.00)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$-0.26	$-0.05	$-0.25 - $0.06
2	$-0.47	$0.19	$-0.22 - $0.37
3	$-0.64	$0.71	$-0.19 - $0.67
4	$-0.77	$1.48	$-0.15 - $0.98
5	$-0.87	$2.50	$-0.12 - $1.28
6	$-0.94	$3.74	$-0.08 - $1.58
7	$-0.98	$5.20	$-0.05 - $1.89
8	$-1.00	$6.86	$-0.02 - $2.19
9	$-1.00	$8.70	$0.02 - $2.50
10	$-0.98	$10.72	$0.05 - $2.80

2. Growth of ADMA Biologics Inc (5 min.)

Is ADMA Biologics Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$135.2m	$123.4m	$21.3m	14.7%

How much money is ADMA Biologics Inc making?

	Current year	Previous year	Grow	Grow %
Making money	-$8.5m	-$24.9m	$16.4m	192.2%
Net Profit Margin	-13.3%	-69.2%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of ADMA Biologics Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#327 / 1010

Most Revenue
#128 / 1010

Most Profit
#533 / 1010

Most Efficient
#472 / 1010

What can you expect buying and holding a share of ADMA Biologics Inc? (5 min.)

Welcome investor! ADMA Biologics Inc's management wants to use your money to grow the business. In return you get a share of ADMA Biologics Inc.

What can you expect buying and holding a share of ADMA Biologics Inc?

First you should know what it really means to hold a share of ADMA Biologics Inc. And how you can make/lose money.

Speculation

The Price per Share of ADMA Biologics Inc is $6.46. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of ADMA Biologics Inc.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in ADMA Biologics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.59. Based on the TTM, the Book Value Change Per Share is $-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $0.01 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of ADMA Biologics Inc.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	-0.08	-1.2%	-0.03	-0.5%	-0.07	-1.1%	-0.06	-1.0%	-0.05	-0.8%
Usd Book Value Change Per Share	-0.06	-0.9%	-0.02	-0.3%	0.01	0.2%	0.03	0.4%	0.01	0.2%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%
Usd Total Gains Per Share	-0.06	-0.9%	-0.02	-0.3%	0.01	0.2%	0.03	0.4%	0.01	0.2%
Usd Price Per Share	4.52	-	3.78	-	2.53	-	2.87	-	4.79	-
Price to Earnings Ratio	-14.62	-	1.52	-	-9.95	-	-8.01	-	-41.66	-
Price-to-Total Gains Ratio	-81.60	-	293.39	-	-22.11	-	16.55	-	-113.60	-
Price to Book Ratio	7.63	-	6.02	-	4.65	-	12.52	-	-173.59	-
Price-to-Total Gains Ratio	-81.60	-	293.39	-	-22.11	-	16.55	-	-113.60	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	6.46
Number of shares	154

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.00
Usd Book Value Change Per Share	-0.02	0.03
Usd Total Gains Per Share	-0.02	0.03
Gains per Quarter (154 shares)	-2.79	3.97
Gains per Year (154 shares)	-11.15	15.89

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	0	-11	-21	0	16	6
2	0	-23	-32	1	31	22
3	0	-34	-43	1	47	38
4	1	-45	-54	1	62	54
5	1	-57	-65	2	78	70
6	1	-68	-76	2	93	86
7	1	-79	-87	2	109	102
8	1	-91	-98	2	125	118
9	1	-102	-109	3	140	134
10	2	-113	-120	3	156	150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	1.0	3.0	0.0	25.0%	1.0	11.0	0.0	8.3%	1.0	19.0	0.0	5.0%	1.0	39.0	0.0	2.5%	1.0	68.0	0.0	1.4%
Book Value Change Per Share	2.0	2.0	0.0	50.0%	5.0	7.0	0.0	41.7%	8.0	12.0	0.0	40.0%	13.0	27.0	0.0	32.5%	18.0	37.0	14.0	26.1%
Dividend per Share	1.0	0.0	3.0	25.0%	2.0	0.0	10.0	16.7%	2.0	0.0	18.0	10.0%	2.0	0.0	38.0	5.0%	2.0	0.0	67.0	2.9%
Total Gains per Share	2.0	2.0	0.0	50.0%	5.0	7.0	0.0	41.7%	8.0	12.0	0.0	40.0%	13.0	27.0	0.0	32.5%	18.0	37.0	14.0	26.1%

Fundamentals of ADMA Biologics Inc

About ADMA Biologics Inc

https://www.admabiologics.com
Biotechnology
624
465 State Route 17, Ramsey, NJ, United States, 07446
Google Maps Bing Maps

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Fundamental data was last updated by Penke on 2024-04-10 23:37:04.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of ADMA Biologics Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit ADMA Biologics Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
A Net Profit Margin of -23.9% means that $-0.24 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ADMA Biologics Inc:

The MRQ is -23.9%. The company is making a huge loss. -2
The TTM is -13.3%. The company is making a huge loss. -2

Trends

Current period		Compared to		+/-
MRQ	-23.9%	TTM	-13.3%	-10.6%
TTM	-13.3%	YOY	-69.2%	+55.9%
TTM	-13.3%	5Y	-113.4%	+100.2%
5Y	-113.4%	10Y	-193.1%	+79.7%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-23.9%	-200.1%	+176.2%
TTM	-13.3%	-216.8%	+203.5%
YOY	-69.2%	-288.3%	+219.1%
5Y	-113.4%	-449.1%	+335.7%
10Y	-193.1%	-605.5%	+412.4%

Measures how much net profit ADMA Biologics Inc earns for each $1 of revenue.

Revenue is the amount of profit ADMA Biologics Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit ADMA Biologics Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, ADMA Biologics Inc makes more profit. This shows the investor how efficiently ADMA Biologics Inc is operating in general and compared to other companies in the same industry. ADMA Biologics Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of ADMA Biologics Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of ADMA Biologics Inc is -0.24. This means that ADMA Biologics Inc earned $-0.24 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -200.1%.
What is the trend?
The trend is important because it shows you how ADMA Biologics Inc is performing over time. The most recent quarter might be important if ADMA Biologics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for ADMA Biologics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare ADMA Biologics Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when ADMA Biologics Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of ADMA Biologics Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of ADMA Biologics Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ ADMA Biologics Inc = -17,645
Total revenue MRQ ADMA Biologics Inc = 73,904
$-17,645 / $73,904 = -0.24 or -23.9%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient ADMA Biologics Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
-5.4% Return on Assets means that ADMA Biologics Inc generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ADMA Biologics Inc:

The MRQ is -5.4%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -2.6%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-5.4%	TTM	-2.6%	-2.8%
TTM	-2.6%	YOY	-8.0%	+5.4%
TTM	-2.6%	5Y	-7.6%	+5.0%
5Y	-7.6%	10Y	-12.5%	+4.9%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-5.4%	-13.3%	+7.9%
TTM	-2.6%	-12.8%	+10.2%
YOY	-8.0%	-11.7%	+3.7%
5Y	-7.6%	-13.9%	+6.3%
10Y	-12.5%	-15.7%	+3.2%

Shows how efficient ADMA Biologics Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively ADMA Biologics Inc is using its resources to generate profit. If the return on assets (-5.4%) from ADMA Biologics Inc are higher than the Biotechnology mean (-13.3%) that means ADMA Biologics Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of ADMA Biologics Inc is -5.4%. This means the company generated $-0.05 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.3%.
What is the trend?
The trend is important because it shows you how ADMA Biologics Inc is performing over time. The most recent quarter might be important if ADMA Biologics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for ADMA Biologics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example ADMA Biologics Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from ADMA Biologics Inc = -17,645
Total assets MRQ (balance sheet) from ADMA Biologics Inc = 329,182
-17,645 / 329,182 = -0.05 or -5.4%

ROA is an important ratio as it will tell you how effectively ADMA Biologics Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient ADMA Biologics Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
-13.1% Return on Equity means ADMA Biologics Inc generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ADMA Biologics Inc:

The MRQ is -13.1%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -6.1%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-13.1%	TTM	-6.1%	-6.9%
TTM	-6.1%	YOY	-20.3%	+14.2%
TTM	-6.1%	5Y	-24.5%	+18.4%
5Y	-24.5%	10Y	-49.2%	+24.7%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-13.1%	-16.9%	+3.8%
TTM	-6.1%	-16.1%	+10.0%
YOY	-20.3%	-15.1%	-5.2%
5Y	-24.5%	-19.3%	-5.2%
10Y	-49.2%	-20.2%	-29.0%

Shows how efficient ADMA Biologics Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of ADMA Biologics Inc is -13.1%. This means ADMA Biologics Inc generated $-0.13 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -16.9%.
What is the trend?
The trend is important because it shows you how ADMA Biologics Inc is performing over time. The most recent quarter might be important if ADMA Biologics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for ADMA Biologics Inc up to 10 years back (depending if ADMA Biologics Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of ADMA Biologics Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) ADMA Biologics Inc = -17,645
Shareholders equity (balance sheet) MRQ ADMA Biologics Inc = 135,206
-17,645 / 135,206 = -0.13 or -13.1%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of ADMA Biologics Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient ADMA Biologics Inc is operating .

Measures how much profit ADMA Biologics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
An Operating Margin of 19.3% means the company generated $0.19 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ADMA Biologics Inc:

The MRQ is 19.3%. The company is operating efficient. +1
The TTM is 7.8%. The company is operating less efficient.

Trends

Current period		Compared to		+/-
MRQ	19.3%	TTM	7.8%	+11.5%
TTM	7.8%	YOY	-28.2%	+35.9%
TTM	7.8%	5Y	-87.6%	+95.4%
5Y	-87.6%	10Y	-167.7%	+80.1%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	19.3%	-296.2%	+315.5%
TTM	7.8%	-232.5%	+240.3%
YOY	-28.2%	-298.2%	+270.0%
5Y	-87.6%	-492.1%	+404.5%
10Y	-167.7%	-632.4%	+464.7%

Measures how efficient ADMA Biologics Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit ADMA Biologics Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of ADMA Biologics Inc is 19.3%. This means that ADMA Biologics Inc earned $0.19 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -296.2%.
What is the trend?
The trend is important because it shows you how ADMA Biologics Inc is performing over time. The most recent quarter might be important if ADMA Biologics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for ADMA Biologics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of ADMA Biologics Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ ADMA Biologics Inc = 14,233
Total revenue MRQ ADMA Biologics Inc = 73,904
$14,233 / $73,904 = 0.19 or 19.3%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient ADMA Biologics Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 0.81 means that the operating costs are $0.81 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ADMA Biologics Inc:

The MRQ is 0.807. The company is less efficient in keeping operating costs low.
The TTM is 0.925. The company is less efficient in keeping operating costs low.

Trends

Current period		Compared to		+/-
MRQ	0.807	TTM	0.925	-0.118
TTM	0.925	YOY	1.282	-0.357
TTM	0.925	5Y	1.882	-0.957
5Y	1.882	10Y	2.677	-0.795

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.807	3.231	-2.424
TTM	0.925	3.310	-2.385
YOY	1.282	3.890	-2.608
5Y	1.882	5.739	-3.857
10Y	2.677	7.876	-5.199

Measures how efficient ADMA Biologics Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of ADMA Biologics Inc is 80.7%. This means that ADMA Biologics Inc earned $0.81 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.23.
What is the trend?
The trend is important because it shows you how ADMA Biologics Inc is performing over time. The most recent quarter might be important if ADMA Biologics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for ADMA Biologics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example ADMA Biologics Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(43,005 +16,666) \ 73,904 = 0.81

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of ADMA Biologics Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if ADMA Biologics Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 5.16 means the company has $5.16 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ADMA Biologics Inc:

The MRQ is 5.160. The company is very able to pay all its short-term debts. +2
The TTM is 6.310. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	5.160	TTM	6.310	-1.149
TTM	6.310	YOY	6.865	-0.556
TTM	6.310	5Y	7.467	-1.157
5Y	7.467	10Y	6.410	+1.057

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	5.160	3.890	+1.270
TTM	6.310	4.173	+2.137
YOY	6.865	5.344	+1.521
5Y	7.467	6.126	+1.341
10Y	6.410	6.448	-0.038

Measures if ADMA Biologics Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for ADMA Biologics Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of ADMA Biologics Inc is 5.16. This means ADMA Biologics Inc has $5.16 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.89.
What is the trend?
The trend is important because it shows you how ADMA Biologics Inc is performing over time. The most recent quarter might be important if ADMA Biologics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for ADMA Biologics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example ADMA Biologics Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
257,013 \ 49,806) = 5.16

The current ratio measures if ADMA Biologics Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if ADMA Biologics Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then ADMA Biologics Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate ADMA Biologics Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if ADMA Biologics Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
A Quick Ratio of 1.58 means the company can pay off $1.58 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ADMA Biologics Inc:

The MRQ is 1.582. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 2.269. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	1.582	TTM	2.269	-0.687
TTM	2.269	YOY	2.352	-0.083
TTM	2.269	5Y	3.372	-1.104
5Y	3.372	10Y	4.413	-1.041

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	1.582	3.514	-1.932
TTM	2.269	3.998	-1.729
YOY	2.352	5.380	-3.028
5Y	3.372	6.105	-2.733
10Y	4.413	6.404	-1.991

Measures if ADMA Biologics Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast ADMA Biologics Inc can pay off its short term debts. This shows if ADMA Biologics Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of ADMA Biologics Inc is 1.58. This means that ADMA Biologics Inc can pay off $1.58 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.51.
What is the trend?
The trend is important because it shows you how ADMA Biologics Inc is performing over time. The most recent quarter might be important if ADMA Biologics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for ADMA Biologics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example ADMA Biologics Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio ADMA Biologics Inc: (51,352 + 0 +27,421) / 49,806 = 1.58

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of ADMA Biologics Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of ADMA Biologics Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare ADMA Biologics Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.59 means that ADMA Biologics Inc assets are financed with 58.9% credit (debt) and the remaining percentage (100% - 58.9%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of ADMA Biologics Inc:

The MRQ is 0.589. The company is able to pay all its debts by selling its assets. +1
The TTM is 0.575. The company is able to pay all its debts by selling its assets. +1

Trends

Current period		Compared to		+/-
MRQ	0.589	TTM	0.575	+0.014
TTM	0.575	YOY	0.608	-0.033
TTM	0.575	5Y	0.613	-0.037
5Y	0.613	10Y	0.713	-0.100

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.589	0.339	+0.250
TTM	0.575	0.336	+0.239
YOY	0.608	0.271	+0.337
5Y	0.613	0.366	+0.247
10Y	0.713	0.389	+0.324

Measures how much % of ADMA Biologics Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake ADMA Biologics Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare ADMA Biologics Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of ADMA Biologics Inc is 0.59. This means means that ADMA Biologics Inc is financed with 58.9% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 389.0%.
What is the trend?
The trend is important because it shows you how ADMA Biologics Inc is performing over time. The most recent quarter might be important if ADMA Biologics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for ADMA Biologics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why ADMA Biologics Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example ADMA Biologics Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
193,976 \ 329,182 = 58.9% or 0.59.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if ADMA Biologics Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 143.5% means that company has $1.43 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ADMA Biologics Inc:

The MRQ is 1.435. The company is able to pay all its debts with equity. +1
The TTM is 1.354. The company is able to pay all its debts with equity. +1

Trends

Current period		Compared to		+/-
MRQ	1.435	TTM	1.354	+0.081
TTM	1.354	YOY	1.577	-0.223
TTM	1.354	5Y	1.869	-0.515
5Y	1.869	10Y	2.654	-0.785

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	1.435	0.388	+1.047
TTM	1.354	0.402	+0.952
YOY	1.577	0.335	+1.242
5Y	1.869	0.426	+1.443
10Y	2.654	0.461	+2.193

Measures if ADMA Biologics Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of ADMA Biologics Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of ADMA Biologics Inc is 1.43. This means that ADMA Biologics Inc can pay off $1.43 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.39.
What is the trend?
The trend is important because it shows you how ADMA Biologics Inc is performing over time. The most recent quarter might be important if ADMA Biologics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for ADMA Biologics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example ADMA Biologics Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
193,976 \ 135,206 = 1.43 or 143.5%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of ADMA Biologics Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings ADMA Biologics Inc generates.

Above 15 is considered overpriced but always compare ADMA Biologics Inc to the Biotechnology industry mean.
A PE ratio of -14.62 means the investor is paying $-14.62 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ADMA Biologics Inc:

The EOD is -20.889. Based on the earnings, the company is expensive. -2
The MRQ is -14.616. Based on the earnings, the company is expensive. -2
The TTM is 1.521. Based on the earnings, the company is cheap. +2

Trends

Current period		Compared to		+/-
EOD	-20.889	MRQ	-14.616	-6.273
MRQ	-14.616	TTM	1.521	-16.137
TTM	1.521	YOY	-9.946	+11.467
TTM	1.521	5Y	-8.007	+9.528
5Y	-8.007	10Y	-41.661	+33.653

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-20.889	-2.264	-18.625
MRQ	-14.616	-2.629	-11.987
TTM	1.521	-2.680	+4.201
YOY	-9.946	-4.145	-5.801
5Y	-8.007	-6.257	-1.750
10Y	-41.661	-6.254	-35.407

Measures how much money you pay for each share for every $1 in earnings ADMA Biologics Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare ADMA Biologics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of ADMA Biologics Inc is -14.62. This means the investor is paying $-14.62 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.63.
What is the trend?
The trend is important because it shows you how ADMA Biologics Inc is performing over time. The most recent quarter might be important if ADMA Biologics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for ADMA Biologics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example ADMA Biologics Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 225,968 = EPS
PE ratio MRQ = -14.62

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ADMA Biologics Inc:

The EOD is 22.767. Based on how much money comes from the company's main activities, the company is underpriced. +1
The MRQ is 15.930. Based on how much money comes from the company's main activities, the company is underpriced. +1
The TTM is -1.786. Based on how much money comes from the company's main activities, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	22.767	MRQ	15.930	+6.837
MRQ	15.930	TTM	-1.786	+17.716
TTM	-1.786	YOY	-9.642	+7.856
TTM	-1.786	5Y	-6.276	+4.490
5Y	-6.276	10Y	-42.925	+36.650

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	22.767	-2.973	+25.740
MRQ	15.930	-3.333	+19.263
TTM	-1.786	-3.553	+1.767
YOY	-9.642	-5.605	-4.037
5Y	-6.276	-8.376	+2.100
10Y	-42.925	-8.865	-34.060

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of ADMA Biologics Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 7.63 means the investor is paying $7.63 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ADMA Biologics Inc:

The EOD is 10.904. Based on the equity, the company is expensive. -2
The MRQ is 7.630. Based on the equity, the company is overpriced. -1
The TTM is 6.020. Based on the equity, the company is overpriced. -1

Trends

Current period		Compared to		+/-
EOD	10.904	MRQ	7.630	+3.275
MRQ	7.630	TTM	6.020	+1.609
TTM	6.020	YOY	4.648	+1.372
TTM	6.020	5Y	12.523	-6.503
5Y	12.523	10Y	-173.591	+186.114

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	10.904	1.896	+9.008
MRQ	7.630	2.115	+5.515
TTM	6.020	2.093	+3.927
YOY	4.648	2.884	+1.764
5Y	12.523	3.542	+8.981
10Y	-173.591	3.916	-177.507

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ADMA Biologics Inc.

3.1. Institutions holding ADMA Biologics Inc

Institutions are holding 77.296% of the shares of ADMA Biologics Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	BlackRock Inc	7.8511	0.0021	17917745	1259538	7.5611
2023-12-31	Vanguard Group Inc	5.6489	0.0013	12891875	110180	0.862
2023-12-31	Nuveen Asset Management, LLC	4.9757	0.0165	11355477	669543	6.2656
2023-12-31	State Street Corporation	4.1555	0.0021	9483590	-118348	-1.2325
2023-12-31	Stonepine Capital Management Llc	4.0411	18.0282	9222617	118342	1.2999
2023-09-30	D. E. Shaw & Co LP	3.3177	0.0283	7571693	-602124	-7.3665
2023-12-31	American Century Companies Inc	2.9851	0.0212	6812691	1920568	39.2584
2023-12-31	Perceptive Advisors LLC	2.8189	0.6491	6433369	-550950	-7.8884
2023-12-31	Magnetar Financial LLC	2.7528	0.721	6282556	408378	6.9521
2023-12-31	Amvescap Plc.	2.678	0.0066	6111773	694607	12.8223
2023-12-31	Awm Investment Company Inc	2.629	3.5675	5999872	0	0
2023-12-31	Geode Capital Management, LLC	2.0366	0.0022	4647937	296324	6.8095
2023-12-31	Assenagon Asset Management SA	1.7287	0.0473	3945225	-1088946	-21.6311
2023-12-31	Morgan Stanley - Brokerage Accounts	1.6581	0.0015	3784183	-1455188	-27.7741
2023-12-31	Dimensional Fund Advisors, Inc.	1.5297	0.0046	3491061	561243	19.1562
2023-12-31	Goldman Sachs Group Inc	1.5182	0.0014	3464782	1217162	54.1534
2023-12-31	Millennium Management LLC	1.5125	0.0068	3451867	-642373	-15.6897
2023-12-31	Driehaus Capital Management LLC	1.4344	0.1783	3273592	-226024	-6.4585
2023-12-31	Two Sigma Investments LLC	1.3605	0.0322	3105010	-82734	-2.5954
2023-12-31	Deutsche Bank AG	1.3388	0.0071	3055316	2947382	2730.7262
Total		57.9713	23.3253	132302231	+5436580	+4.1%

3.2. Funds holding ADMA Biologics Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2024-02-29	Vanguard Total Stock Mkt Idx Inv	2.8094	0.0022	6411673	0	0
2024-02-29	iShares Russell 2000 ETF	2.2458	0.0441	5125292	-838	-0.0163
2024-02-29	SPDR® S&P Biotech ETF	2.2418	0.3463	5116277	95580	1.9037
2024-01-31	CREF Stock R1	1.7449	0.0175	3982325	0	0
2024-02-29	Vanguard Institutional Extnd Mkt Idx Tr	1.3708	0.0164	3128330	-3152	-0.1007
2023-12-31	American Century Small Cap Growth Inv	1.3156	0.4235	3002454	881148	41.538
2023-12-31	American Century U.S. Small Cap Growth	1.3156	0.4235	3002454	881148	41.538
2024-01-31	Invesco Main Street Small Cap R6	1.2042	0.8527	2748305	0	0
2023-12-31	Invesco Small Cap Core	1.2042	0.7304	2748305	109710	4.1579
2023-12-31	Oberweis Micro-Cap Growth	1.1878	2.7096	2710700	632300	30.4224
2023-12-31	Oberweis Micro-Cap	1.1878	2.7118	2710700	632300	30.4224
2023-12-31	Fidelity Small Cap Index	0.9297	0.0377	2121782	49219	2.3748
2024-01-31	TIAA-CREF Quant Small-Cap Equity Instl	0.7559	0.2989	1725090	0	0
2024-02-29	iShares Biotechnology ETF	0.7273	0.117	1659781	-7470	-0.448
2024-01-31	Invesco V.I. Main Street Small Cap I	0.5876	0.8585	1341053	0	0
2024-02-29	State St Russell Sm/Mid Cp® Indx NL Cl C	0.5833	0.0171	1331281	42900	3.3298
2024-02-29	Nuveen Small-Cap Value Opps I	0.5575	3.5122	1272352	0	0
2024-01-31	Fidelity Extended Market Index	0.5136	0.017	1172076	10237	0.8811
2024-02-29	Nuveen Multi Cap Value I	0.5029	1.8384	1147743	63839	5.8897
2024-02-29	iShares Russell 2000 Growth ETF	0.4363	0.047	995772	-1158	-0.1162
Total		23.422	15.0218	53453745	+3385763	+6.3%

3.3. Insider Transactions

Insiders are holding 2.501% of the shares of ADMA Biologics Inc.

Date	Owner	Type	Amount	Price
2024-03-18	Steve Elms	SELL	49887	6.01
2024-03-15	Steve Elms	SELL	183008	6.01
2024-03-13	Steve Elms	SELL	407000	6.21
2023-08-30	Jerrold B Grossman	BUY	130000	3.71
2023-08-24	Young Kwon	BUY	25000	3.9
2023-08-22	Bryant Fong	SELL	1433304	3.87
2023-08-18	Adam S Grossman	SELL	250000	4.15
2023-08-15	Adam S Grossman	SELL	510469	4.54
2023-08-15	Brian Lenz	SELL	211578	4.6

4. Summary

4.1. Key Performance Indicators

The key performance indicators of ADMA Biologics Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	-0.055	-0.018	-67%	0.012	-568%	0.025	-319%	0.012	-545%
Book Value Per Share	-	-	0.592	0.630	-6%	0.541	+10%	0.436	+36%	0.248	+139%
Current Ratio	-	-	5.160	6.310	-18%	6.865	-25%	7.467	-31%	6.410	-19%
Debt To Asset Ratio	-	-	0.589	0.575	+2%	0.608	-3%	0.613	-4%	0.713	-17%
Debt To Equity Ratio	-	-	1.435	1.354	+6%	1.577	-9%	1.869	-23%	2.654	-46%
Dividend Per Share	-	-	-	0.000	-100%	0.002	-100%	0.001	-100%	0.000	-100%
Eps	-	-	-0.077	-0.031	-60%	-0.072	-7%	-0.064	-18%	-0.050	-36%
Free Cash Flow Per Share	-	-	0.071	0.004	+1723%	-0.080	+213%	-0.086	+221%	-0.060	+184%
Free Cash Flow To Equity Per Share	-	-	-0.100	-0.039	-61%	0.039	-357%	0.005	-1976%	0.001	-9713%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Intrinsic Value_10Y_max	-	-	10.724	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-0.978	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	-0.049	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-0.256	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	0.709	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-0.636	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	2.499	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-0.869	-	-	-	-	-	-	-	-
Market Cap	1474301200.000	+30%	1031554400.000	866489929.490	+19%	577396600.000	+79%	655755065.898	+57%	1092642752.949	-6%
Net Profit Margin	-	-	-0.239	-0.133	-44%	-0.692	+190%	-1.134	+375%	-1.931	+709%
Operating Margin	-	-	0.193	0.078	+148%	-0.282	+246%	-0.876	+555%	-1.677	+971%
Operating Ratio	-	-	0.807	0.925	-13%	1.282	-37%	1.882	-57%	2.677	-70%
Pb Ratio	10.904	+30%	7.630	6.020	+27%	4.648	+64%	12.523	-39%	-173.591	+2375%
Pe Ratio	-20.889	-43%	-14.616	1.521	-1061%	-9.946	-32%	-8.007	-45%	-41.661	+185%
Price Per Share	6.460	+30%	4.520	3.775	+20%	2.530	+79%	2.869	+58%	4.786	-6%
Price To Free Cash Flow Ratio	22.767	+30%	15.930	-1.786	+111%	-9.642	+161%	-6.276	+139%	-42.925	+369%
Price To Total Gains Ratio	-116.623	-43%	-81.600	293.387	-128%	-22.113	-73%	16.549	-593%	-113.597	+39%
Quick Ratio	-	-	1.582	2.269	-30%	2.352	-33%	3.372	-53%	4.413	-64%
Return On Assets	-	-	-0.054	-0.026	-52%	-0.080	+49%	-0.076	+42%	-0.125	+133%
Return On Equity	-	-	-0.131	-0.061	-53%	-0.203	+56%	-0.245	+88%	-0.492	+277%
Total Gains Per Share	-	-	-0.055	-0.018	-67%	0.014	-493%	0.026	-315%	0.013	-536%
Usd Book Value	-	-	135206000.000	144765065.250	-7%	123423085.750	+10%	99644975.450	+36%	56574800.175	+139%
Usd Book Value Change Per Share	-	-	-0.055	-0.018	-67%	0.012	-568%	0.025	-319%	0.012	-545%
Usd Book Value Per Share	-	-	0.592	0.630	-6%	0.541	+10%	0.436	+36%	0.248	+139%
Usd Dividend Per Share	-	-	-	0.000	-100%	0.002	-100%	0.001	-100%	0.000	-100%
Usd Eps	-	-	-0.077	-0.031	-60%	-0.072	-7%	-0.064	-18%	-0.050	-36%
Usd Free Cash Flow	-	-	16188738.000	954750.000	+1596%	-18354857.000	+213%	-19510782.400	+221%	-13643826.325	+184%
Usd Free Cash Flow Per Share	-	-	0.071	0.004	+1723%	-0.080	+213%	-0.086	+221%	-0.060	+184%
Usd Free Cash Flow To Equity Per Share	-	-	-0.100	-0.039	-61%	0.039	-357%	0.005	-1976%	0.001	-9713%
Usd Market Cap	1474301200.000	+30%	1031554400.000	866489929.490	+19%	577396600.000	+79%	655755065.898	+57%	1092642752.949	-6%
Usd Price Per Share	6.460	+30%	4.520	3.775	+20%	2.530	+79%	2.869	+58%	4.786	-6%
Usd Profit	-	-	-17644533.000	-8553624.250	-52%	-24992171.500	+42%	-16492933.300	-7%	-12341483.250	-30%
Usd Revenue	-	-	73903677.000	64553750.000	+14%	38519923.000	+92%	28240309.150	+162%	15707656.200	+370%
Usd Total Gains Per Share	-	-	-0.055	-0.018	-67%	0.014	-493%	0.026	-315%	0.013	-536%
	EOD	+4 -4	MRQ	TTM	+10 -25	YOY	+19 -16	5Y	+19 -16	10Y	+16 -19

4.2. Fundamental Score

Let's check the fundamental score of ADMA Biologics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-20.889
Price to Book Ratio (EOD)	Between	0-1	10.904
Net Profit Margin (MRQ)	Greater than	0	-0.239
Operating Margin (MRQ)	Greater than	0	0.193
Quick Ratio (MRQ)	Greater than	1	1.582
Current Ratio (MRQ)	Greater than	1	5.160
Debt to Asset Ratio (MRQ)	Less than	1	0.589
Debt to Equity Ratio (MRQ)	Less than	1	1.435
Return on Equity (MRQ)	Greater than	0.15	-0.131
Return on Assets (MRQ)	Greater than	0.05	-0.054
Total			4/10 (40.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of ADMA Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	58.000
Ma 20	Greater than	Ma 50	6.290
Ma 50	Greater than	Ma 100	5.993
Ma 100	Greater than	Ma 200	5.309
Open	Greater than	Close	6.540
Total			5/5 (100.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

		2022-12-31		2023-03-31		2023-06-30		2023-09-30		2023-12-31
Income Tax Expense		13,699	-7,724	5,975	311	6,286	-35	6,252	-6,252	0

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	329,182
Total Liabilities	193,976
Total Stockholder Equity	135,206

	As reported
Total Liabilities	193,976
Total Stockholder Equity	+ 135,206
Total Assets	= 329,182

Assets

Total Assets	329,182
Total Current Assets	257,013
Long-term Assets	72,169

Total Current Assets

Total Current Assets (as reported)	257,013
Cash And Cash Equivalents	51,352
Net Receivables	27,421
Inventory	172,906
Other Current Assets	5,334
Total Current Assets (calculated)	257,013
+/-	0

Long-term Assets

Long-term Assets (as reported)	72,169
Property Plant Equipment	63,470
Goodwill	3,530
Intangible Assets	499
Long-term Assets Other	4,670
Long-term Assets (calculated)	72,169
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	49,806
Long-term Liabilities	144,170
Total Stockholder Equity	135,206

Total Current Liabilities

Total Current Liabilities (as reported)	49,806
Short-term Debt	1,045
Accounts payable	15,660
Other Current Liabilities	32,919
Total Current Liabilities (calculated)	49,624
+/-	182

Long-term Liabilities

Long-term Liabilities (as reported)	144,170
Long term Debt	130,594
Capital Lease Obligations	10,824
Long-term Liabilities Other	2,107
Long-term Liabilities (calculated)	143,525
+/-	645

Total Stockholder Equity

Total Stockholder Equity (as reported)	135,206
Common Stock	23
Retained Earnings	-506,256
Other Stockholders Equity	641,439
Total Stockholder Equity (calculated)	135,206
+/-	0

Other

Capital Stock	23
Cash and Short Term Investments	51,352
Common Stock Shares Outstanding	225,968
Current Deferred Revenue	182
Liabilities and Stockholders Equity	329,182
Net Debt	90,066
Net Invested Capital	265,800
Net Working Capital	207,207
Property Plant and Equipment Gross	90,207
Short Long Term Debt Total	141,418

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

> Total Assets

11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
3
16
9
6
8
17,008
15,884
13,225
15,555
13,817
10,690
8,702
31,980
31,951
27,883
25,287
27,227
33,928
29,800
27,824
23,715
19,685
31,742
27,495
23,685
17,595
84,639
72,813
108,019
91,138
117,752
106,345
88,877
78,120
143,274
137,780
127,091
210,524
191,542
189,976
207,673
235,667
232,814
238,640
276,253
308,032
296,932
300,558
348,462
340,788
343,027
348,997
329,182

329,182

348,997

343,027

340,788

348,462

300,558

296,932

308,032

276,253

238,640

232,814

235,667

207,673

189,976

191,542

210,524

127,091

137,780

143,274

78,120

88,877

106,345

117,752

91,138

108,019

72,813

84,639

17,595

23,685

27,495

31,742

19,685

23,715

27,824

29,800

33,928

27,227

25,287

27,883

31,951

31,980

8,702

10,690

13,817

15,555

13,225

15,884

17,008

3,619

2,934

6,844

9,270

8,688

10,108

8,028

2,647

6,569

8,787

7,805

14,652

16,663

9,033

11,253

> Total Current Assets

11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
3
16
9
6
8
15,844
14,619
11,982
13,948
12,306
9,173
7,144
31,052
30,788
26,494
22,572
24,088
30,982
27,127
25,240
21,290
17,358
29,494
25,360
21,657
15,683
44,271
31,444
63,167
46,419
73,630
62,503
44,530
38,334
103,889
97,323
85,820
165,488
142,990
139,549
153,741
177,277
171,355
174,785
208,729
239,800
222,774
224,095
270,402
264,086
266,243
273,699
257,013

257,013

273,699

266,243

264,086

270,402

224,095

222,774

239,800

208,729

174,785

171,355

177,277

153,741

139,549

142,990

165,488

85,820

97,323

103,889

38,334

44,530

62,503

73,630

46,419

63,167

31,444

44,271

15,683

21,657

25,360

29,494

17,358

21,290

25,240

27,127

30,982

24,088

22,572

26,494

30,788

31,052

7,144

9,173

12,306

13,948

11,982

14,619

15,844

3,619

2,934

6,844

9,270

8,688

10,108

8,028

2,647

6,569

8,787

7,805

14,652

16,663

9,033

11,253

Cash And Cash Equivalents

11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
3
16
9
6
8
14,240
12,888
10,720
12,536
10,321
7,653
5,380
26,149
26,518
17,869
13,952
17,199
16,564
7,822
9,178
10,441
8,925
12,549
7,906
9,915
8,543
25,574
13,601
43,108
26,120
55,154
42,367
22,755
16,534
73,616
48,006
26,752
101,236
75,781
59,675
55,921
61,966
42,409
34,411
51,089
69,505
52,415
34,906
86,522
69,204
62,513
74,157
51,352

51,352

74,157

62,513

69,204

86,522

34,906

52,415

69,505

51,089

34,411

42,409

61,966

55,921

59,675

75,781

101,236

26,752

48,006

73,616

16,534

22,755

42,367

55,154

26,120

43,108

13,601

25,574

8,543

9,915

7,906

12,549

8,925

10,441

9,178

7,822

16,564

17,199

13,952

17,869

26,518

26,149

5,380

7,653

10,321

12,536

10,720

12,888

14,240

3,619

2,934

6,844

9,270

8,688

10,108

8,028

2,647

6,569

8,787

7,805

14,652

16,663

9,033

11,253

Short-term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,935
2,203
6,314
6,320
4,653
11,512
15,930
11,764
6,368
2,695
11,271
11,027
5,390
245
0
0
1,500
1,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1,500

245

5,390

11,027

11,271

2,695

6,368

11,764

15,930

11,512

4,653

6,320

6,314

2,203

2,935

Net Receivables

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
220
62
39
326
237
335
0
484
804
562
384
351
522
1,201
924
944
827
1,328
1,018
840
2,292
1,500
3,880
3,658
3,797
4,127
1,392
1,310
5,087
7,315
3,470
7,108
6,514
6,335
13,237
15,362
23,545
20,393
28,577
25,630
18,884
20,902
15,505
26,518
36,732
31,319
27,421

27,421

31,319

36,732

26,518

15,505

20,902

18,884

25,630

28,577

20,393

23,545

15,362

13,237

6,335

6,514

7,108

3,470

7,315

5,087

1,310

1,392

4,127

3,797

3,658

3,880

1,500

2,292

840

1,018

1,328

827

944

924

1,201

522

351

384

562

804

484

335

237

326

220

Other Current Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
428
308
190
108
651
367
223
299
598
395
286
144
613
399
267
111
745
638
482
314
747
2,408
2,079
2,051
2,703
2,431
2,131
1,766
2,050
1,597
1,716
2,534
4,855
4,693
3,786
3,046
5,803
5,702
5,859
4,339
5,519
5,400
5,372
5,095
4,379
5,219
5,107
5,334

5,334

5,107

5,219

4,379

5,095

5,372

5,400

5,519

4,339

5,859

5,702

5,803

3,046

3,786

4,693

4,855

2,534

1,716

1,597

2,050

1,766

2,131

2,431

2,703

2,051

2,079

2,408

747

314

482

638

745

111

267

399

613

144

286

395

598

299

223

367

651

108

190

308

428

> Long-term Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,165
1,265
1,243
1,607
1,512
1,518
1,558
927
1,164
1,389
2,716
3,139
2,946
2,673
2,584
2,424
2,327
2,248
2,136
2,028
1,912
40,368
41,369
44,852
44,718
44,122
43,842
44,347
39,786
39,385
40,456
41,270
45,036
48,552
50,428
53,933
58,390
61,459
63,855
67,523
68,232
74,158
76,463
78,060
76,701
76,784
75,298
72,169

72,169

75,298

76,784

76,701

78,060

76,463

74,158

68,232

67,523

63,855

61,459

58,390

53,933

50,428

48,552

45,036

41,270

40,456

39,385

39,786

44,347

43,842

44,122

44,718

44,852

41,369

40,368

1,912

2,028

2,136

2,248

2,327

2,424

2,584

2,673

2,946

3,139

2,716

1,389

1,164

927

1,558

1,518

1,512

1,607

1,243

1,265

1,165

Property Plant Equipment

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
815
825
804
779
802
850
811
765
829
1,039
2,381
2,841
2,738
2,628
2,519
2,397
2,296
2,221
2,109
2,001
1,882
28,627
29,756
30,467
30,616
30,337
30,363
30,116
29,695
29,444
30,713
31,741
35,061
37,373
42,405
45,852
50,373
53,316
55,085
58,198
60,327
65,502
67,282
68,747
67,618
66,309
64,568
63,470

63,470

64,568

66,309

67,618

68,747

67,282

65,502

60,327

58,198

55,085

53,316

50,373

45,852

42,405

37,373

35,061

31,741

30,713

29,444

29,695

30,116

30,363

30,337

30,616

30,467

29,756

28,627

1,882

2,001

2,109

2,221

2,296

2,397

2,519

2,628

2,738

2,841

2,381

1,039

829

765

811

850

802

779

804

825

815

Goodwill

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530

3,530

Intangible Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,011
5,737
4,849
4,638
4,427
4,216
4,004
3,793
3,582
3,371
3,159
2,981
2,802
2,623
2,444
2,265
2,086
1,908
1,729
1,550
1,371
1,192
1,013
835
656
477
499

499

477

656

835

1,013

1,192

1,371

1,550

1,729

1,908

2,086

2,265

2,444

2,623

2,802

2,981

3,159

3,371

3,582

3,793

4,004

4,216

4,427

4,638

4,849

5,737

6,011

Other Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
349
440
439
828
709
668
747
163
335
350
334
298
208
45
65
28
31
27
27
27
30
11,742
11,614
14,385
5,935
5,829
5,735
6,697
2,768
2,829
2,843
2,840
3,465
4,847
4,653
6,366
2,223
2,527
3,334
4,067
2,826
3,756
4,459
4,770
0
6,289
0
0

6,289

4,770

4,459

3,756

2,826

4,067

3,334

2,527

2,223

6,366

4,653

4,847

3,465

2,840

2,843

2,829

2,768

6,697

5,735

5,829

5,935

14,385

11,614

11,742

208

298

334

350

335

163

747

668

709

828

439

440

349

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
245
203
282
150
308
323
307
272
181
18
38
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

181

272

307

323

308

150

282

203

245

> Total Liabilities

11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
5
6
10
10
5
1,258
1,228
1,618
6,132
7,417
8,962
9,438
10,407
16,048
15,580
16,042
21,219
20,497
20,280
22,910
22,894
23,054
27,826
27,648
28,142
28,353
56,957
59,821
67,686
68,112
65,993
69,139
69,106
68,081
96,368
101,662
100,898
114,188
114,662
118,600
119,424
123,163
121,220
135,860
135,080
181,099
182,532
200,173
196,488
195,133
196,265
197,559
193,976

193,976

197,559

196,265

195,133

196,488

200,173

182,532

181,099

135,080

135,860

121,220

123,163

119,424

118,600

114,662

114,188

100,898

101,662

96,368

68,081

69,106

69,139

65,993

68,112

67,686

59,821

56,957

28,353

28,142

27,648

27,826

23,054

22,894

22,910

20,280

20,497

21,219

16,042

15,580

16,048

10,407

9,438

8,962

7,417

6,132

1,618

1,228

1,258

3,619

2,934

6,844

9,270

8,688

10,108

8,028

2,647

6,569

8,787

7,805

14,652

16,663

9,033

11,253

> Total Current Liabilities

3,616
3,866
3,572
10,072
8,508
8,409
11,058
15,958
15,958
7,458
6,858
11,508
9,908
5,808
6,708
12
8,608
5
6
10
10
5
1,027
1,006
1,404
1,817
2,101
2,029
2,517
3,658
4,303
3,797
4,119
4,198
3,787
3,200
4,298
4,217
4,291
5,083
9,208
11,223
12,958
15,645
13,339
9,440
9,443
6,917
9,893
9,625
8,338
10,129
15,150
14,028
13,908
12,880
16,474
19,947
21,206
18,186
32,337
30,378
31,567
28,072
44,440
39,267
36,728
41,952
41,841
49,806

49,806

41,841

41,952

36,728

39,267

44,440

28,072

31,567

30,378

32,337

18,186

21,206

19,947

16,474

12,880

13,908

14,028

15,150

10,129

8,338

9,625

9,893

6,917

9,443

9,440

13,339

15,645

12,958

11,223

9,208

5,083

4,291

4,217

4,298

3,200

3,787

4,198

4,119

3,797

4,303

3,658

2,517

2,029

2,101

1,817

1,404

1,006

1,027

8,608

6,708

5,808

9,908

11,508

6,858

7,458

15,958

11,058

8,409

8,508

10,072

3,572

3,866

3,616

Short-term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
10
12
12
12
12
13
13
13
14
14
14
14
15
15
15
16
4,461
6,128
6,684
6,667
3,860
3,318
40,467
29
29
30
210
223
230
229
194
211
276
366
318
386
501
591
654
580
721
905
956
980
983
1,045

1,045

983

980

956

905

721

580

654

591

501

386

318

366

276

211

194

229

230

223

210

40,467

3,318

3,860

6,667

6,684

6,128

4,461

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
0
0
0
15
0
0
0
6,111
17,544
30,855
29,369
40,211
40,467
40,899
0
0
210
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

210

40,899

40,467

40,211

29,369

30,855

17,544

6,111

Accounts payable

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
5
509
791
891
1,059
1,379
1,159
1,483
2,709
2,764
2,340
2,445
1,779
1,779
1,648
2,185
2,088
2,468
3,317
2,777
2,565
3,904
4,672
9,156
5,921
5,718
3,101
5,268
5,900
5,480
6,788
8,960
9,175
9,152
6,910
7,980
11,074
12,153
6,167
17,283
12,429
14,115
11,388
25,198
13,229
12,956
12,085
10,851
15,660

15,660

10,851

12,085

12,956

13,229

25,198

11,388

14,115

12,429

17,283

6,167

12,153

11,074

7,980

6,910

9,152

9,175

8,960

6,788

5,480

5,900

5,268

3,101

5,718

5,921

9,156

4,672

3,904

2,565

2,777

3,317

2,468

2,088

2,185

1,648

1,779

2,445

2,340

2,764

2,709

1,483

1,159

1,379

1,059

891

791

509

Other Current Liabilities

3,616
3,866
3,572
10,072
8,508
8,409
11,058
15,958
0
7,458
6,858
11,508
9,908
5,808
6,708
12
8,608
5
6
10
10
5
508
205
503
747
710
789
947
860
1,451
1,368
1,585
2,329
1,918
1,463
1,949
1,968
1,662
1,605
1,825
2,385
2,225
4,161
177
58
3,582
3,644
4,453
3,552
2,506
2,974
4,763
4,481
4,419
5,617
8,075
8,365
8,592
11,490
14,410
17,215
16,655
15,961
18,379
24,989
22,672
28,746
29,864
32,919

32,919

29,864

28,746

22,672

24,989

18,379

15,961

16,655

17,215

14,410

11,490

8,592

8,365

8,075

5,617

4,419

4,481

4,763

2,974

2,506

3,552

4,453

3,644

3,582

177

4,161

2,225

2,385

1,825

1,605

1,662

1,968

1,949

1,463

1,918

2,329

1,585

1,368

1,451

860

947

789

710

747

503

205

508

8,608

6,708

5,808

9,908

11,508

6,858

7,458

15,958

11,058

8,409

8,508

10,072

3,572

3,866

3,616

> Long-term Liabilities

3,616
3,866
3,572
10,072
8,508
8,409
11,058
15,958
15,958
7,458
6,858
11,508
9,908
5,808
6,708
0
8,608
0
0
0
0
0
231
222
214
4,314
5,316
6,933
6,921
6,749
11,744
11,784
11,924
17,021
16,710
17,080
18,612
18,677
18,763
22,743
18,440
16,919
15,395
41,312
46,482
58,246
58,669
59,076
59,246
59,481
59,743
86,240
86,512
86,870
100,280
101,782
102,127
99,477
101,957
103,034
103,523
104,702
149,533
154,460
155,733
157,221
158,405
154,312
155,718
144,170

144,170

155,718

154,312

158,405

157,221

155,733

154,460

149,533

104,702

103,523

103,034

101,957

99,477

102,127

101,782

100,280

86,870

86,512

86,240

59,743

59,481

59,246

59,076

58,669

58,246

46,482

41,312

15,395

16,919

18,440

22,743

18,763

18,677

18,612

17,080

16,710

17,021

11,924

11,784

11,744

6,749

6,921

6,933

5,316

4,314

214

222

231

8,608

6,708

5,808

9,908

11,508

6,858

7,458

15,958

11,058

8,409

8,508

10,072

3,572

3,866

3,616

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87
84
81
3,851
4,869
4,888
4,909
4,930
9,736
9,765
9,915
14,824
14,940
14,037
14,156
14,283
14,413
18,078
13,818
12,341
10,861
11,151
16,324
28,128
28,377
28,772
29,040
29,320
42,347
83,774
84,095
69,594
97,961
99,511
99,904
0
0
0
0
0
0
0
0
0
0
0
0
0

99,904

99,511

97,961

69,594

84,095

83,774

42,347

29,320

29,040

28,772

28,377

28,128

16,324

11,151

10,861

12,341

13,818

18,078

14,413

14,283

14,156

14,037

14,940

14,824

9,915

9,765

9,736

4,930

4,909

4,888

4,869

3,851

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
245
203
282
150
308
323
307
272
181
18
38
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

181

272

307

323

308

150

282

203

245

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
144
138
133
356
313
1,911
1,878
1,686
1,875
1,886
1,876
2,064
1,637
1,610
3,024
2,962
2,918
2,875
2,832
2,787
2,744
2,712
2,701
15,275
18,203
18,206
18,100
18,047
2,514
2,465
2,417
2,368
2,319
2,271
2,222
2,173,584
2,125
2,083
2,244
2,373
3,826
3,778
3,731
3,683
0
3,778
0
0

3,778

3,683

3,731

3,778

3,826

2,373

2,244

2,083

2,125

2,173,584

2,222

2,271

2,319

2,368

2,417

2,465

2,514

18,047

18,100

18,206

18,203

15,275

2,701

2,712

2,744

2,787

2,832

2,875

2,918

2,962

3,024

1,610

1,637

2,064

1,876

1,886

1,875

1,686

1,878

1,911

313

356

133

138

144

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
144
139
133
128
315
1,913
1,879
1,686
1,876
1,886
1,876
2,065
1,638
1,611
3,023
2,962
2,918
2,875
2,831
2,788
2,745
2,619
2,583
2,547
2,511
2,476
2,440
2,404
2,369
2,333
2,297
2,262
2,226
2,190
2,154
0
0
0
0
0
0
0
0
0
0
0
0
0

2,154

2,190

2,226

2,262

2,297

2,333

2,369

2,404

2,440

2,476

2,511

2,547

2,583

2,619

2,745

2,788

2,831

2,875

2,918

2,962

3,023

1,611

1,638

2,065

1,876

1,886

1,876

1,686

1,879

1,913

315

128

133

139

144

> Total Stockholder Equity

7,637
5,167
13,091
4,580
-703
378
-4,489
-13,311
0
570
3,250
-2,820
-638
1,036
-3,774
0
-4,989
-2
10
-1
-4
3
15,750
14,656
11,607
9,424
6,401
1,728
-736
21,573
15,904
12,303
9,245
6,009
13,430
9,520
4,914
821
-3,369
3,916
-152
-4,457
-10,758
27,682
12,993
40,333
23,025
51,759
37,206
19,770
10,039
46,906
36,118
26,193
96,336
76,879
71,376
88,249
112,504
111,594
102,780
141,173
126,933
114,401
100,385
151,974
145,655
146,762
151,437
135,206

135,206

151,437

146,762

145,655

151,974

100,385

114,401

126,933

141,173

102,780

111,594

112,504

88,249

71,376

76,879

96,336

26,193

36,118

46,906

10,039

19,770

37,206

51,759

23,025

40,333

12,993

27,682

-10,758

-4,457

-152

3,916

-3,369

821

4,914

9,520

13,430

6,009

9,245

12,303

15,904

21,573

-736

1,728

6,401

9,424

11,607

14,656

15,750

-4

-1

-2

-4,989

-3,774

1,036

-638

-2,820

3,250

570

-13,311

-4,489

378

-703

4,580

13,091

5,167

7,637

Common Stock

0
0
0
0
0
0
0
250
0
250
250
250
250
250
250
0
250
0
0
0
0
0
5
5
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3
3
5
5
5
5
5
5
6
6
6
9
9
9
10
12
13
14
20
20
20
20
22
22
22
23
23

250

Retained Earnings

-506,256

-488,611

-491,176

-484,805

-478,017

-465,785

-450,885

-437,121

-412,113

-395,463

-377,750

-358,845

-340,465

-321,057

-304,140

-283,962

-264,717

-254,156

-242,717

-229,505

-216,437

-198,399

-183,264

-168,516

-150,694

-137,711

-122,508

-113,472

-106,935

-102,376

-98,044

-92,032

-87,420

-82,837

-77,735

-73,055

-69,450

-65,886

-62,502

-58,540

-52,637

-47,935

-45,246

-40,351

-37,109

-34,858

-31,612

-30,405

-154

-145

-140

-128

-123

-118

-114

-38

-33

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
141
156
46,151
46,263
46,464
46,533
46,751
46,974
47,199
74,209
74,443
74,803
75,130
75,457
86,485
87,253
87,750
88,240
88,662
101,959
102,222
102,476
102,712
150,188
150,701
191,022
191,537
235,018
235,601
236,203
239,540
289,617
290,268
290,904
380,289
381,011
392,424
428,704
471,337
489,331
498,230
553,266
564,034
565,266
566,150
629,969
630,438
637,916
0
0

637,916

630,438

629,969

566,150

565,266

564,034

553,266

498,230

489,331

471,337

428,704

392,424

381,011

380,289

290,904

290,268

289,617

239,540

236,203

235,601

235,018

191,537

191,022

150,701

150,188

102,712

102,476

102,222

101,959

88,662

88,240

87,750

87,253

86,485

75,457

75,130

74,803

74,443

74,209

47,199

46,974

46,751

46,533

46,464

46,263

46,151

156

141

Treasury Stock

Other Stockholders Equity

7,670
5,205
13,091
4,580
-703
378
-4,489
-13,561
0
320
3,000
-3,070
-888
786
-4,024
113
-5,121
122
139
139
141
156
46,151
46,263
46,464
46,533
46,751
46,974
47,199
75,245
74,443
74,803
75,130
76,741
86,485
87,253
87,750
89,993
88,662
101,959
102,222
104,700
102,712
150,547
151,520
192,308
193,340
237,356
238,481
239,624
243,619
294,288
295,539
296,629
380,289
381,011
392,424
428,704
471,337
489,331
498,230
553,266
564,034
565,266
566,150
629,969
630,438
637,916
640,026
641,439

641,439

640,026

637,916

630,438

629,969

566,150

565,266

564,034

553,266

498,230

489,331

471,337

428,704

392,424

381,011

380,289

296,629

295,539

294,288

243,619

239,624

238,481

237,356

193,340

192,308

151,520

150,547

102,712

104,700

102,222

101,959

88,662

89,993

87,750

87,253

86,485

76,741

75,130

74,803

74,443

75,245

47,199

46,974

46,751

46,533

46,464

46,263

46,151

156

141

139

122

-5,121

113

-4,024

786

-888

-3,070

3,000

320

-13,561

-4,489

378

-703

4,580

13,091

5,205

7,670

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Accounts Payable	15,660	13,229	12,429	11,074	9,175	5,900	5,921	2,565	2,088	1,779	2,709	1,059	0	800	0	0	0	0
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	0	0	0	0	-5,725	-3,421	-1,286	-2,223	-1,754	-1,284	-1,036	-825	-700	-500	0	0	0	0
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	10,824	11,610	8,053	4,700	1,302	119	0	20	36	51	65	78	0	0	0	0	0	0
Capital Stock	23	22	20	10	6	5	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	629,969	553,266	428,704	290,904	236,203	191,022	102,476	88,240	75,457	74,209	46,533	0	0	0	0	0	0
Cash	51,352	86,522	51,089	55,921	26,752	22,755	43,108	9,915	10,441	17,199	26,149	12,536	9	12	8,688	2,647	14,652	14,652
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	51,352	86,522	51,089	55,921	26,752	22,755	43,108	15,305	16,809	21,852	29,085	12,536	9	12	8,688	2,647	14,652	0
Common Stock	23	22	20	10	6	5	5	1	1	1	1	0	0	0	250	250	0	0
Common Stock Shares Outstanding	223,977	197,875	139,579	86,145	54,348	45,189	22,896	12,153	10,412	9,292	6,531	5,266	2,500	2,500	2,500	2,500	2,500	2,500
Common Stock Total Equity	0	22	20	10	6	5	5	1	1	1	1	0	0	0	250	250	250	0
Current Deferred Revenue	182	143	143	143	143	143	143	145	145	76	76	0	0	0	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	272	150	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	2,262	2,404	2,547	2,788	2,962	2,065	1,686	128	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	3,530	3,530	3,530	3,530	3,530	3,530	3,530	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	499	1,013	1,729	2,444	3,159	4,004	4,849	0	0	0	0	0	0	0	0	0	0	0
Inventory	172,906	163,280	124,724	81,536	53,065	18,616	12,628	5,020	3,446	1,709	1,669	1,266	1,100	3,400	0	0	0	0
Liabilities And Stockholders Equity	329,182	348,462	276,253	207,673	127,091	88,877	108,019	23,685	23,715	27,227	31,980	15,555	9	12	8,688	2,647	14,652	19,232
Long Term Debt	130,594	142,833	94,866	92,969	68,291	29,201	28,128	12,322	14,247	14,772	4,865	3,774	0	0	0	0	0	0
Long Term Debt Total	0	0	0	0	69,594	29,320	28,128	12,341	14,283	14,824	4,930	3,851	0	0	0	0	0	0
Long Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	90,066	67,921	51,831	41,748	57,979	21,469	-137	10,344	5,290	-2,229	-21,074	-8,567	9,809	7,188	2,820	13,311	-4,580	-4,580
Net Invested Capital	265,800	294,807	236,039	181,218	109,392	63,845	83,304	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	27,421	15,505	28,577	13,237	3,470	1,392	3,880	1,018	924	384	484	39	0	-3,500	0	0	0	0
Net Tangible Assets	0	151,974	141,173	82,275,796	19,504	12,237	31,954	-4,457	821	6,009	21,573	9,424	0	0	0	0	0	0
Net Working Capital	207,207	231,135	178,351	133,793	71,792	34,905	53,726	10,434	17,074	19,890	27,395	12,131	-1	0	-2,820	-13,311	4,580	4,580
Non Current Assets Total	72,169	78,060	67,523	53,933	41,270	44,347	44,852	2,028	2,424	3,139	927	1,607	1,600	1,500	0	0	0	0
Non Current Liabilities Other	2,107	1,850	397	55	15,015	27,757	27,570	1,790	1,432	133	133	335	0	0	0	0	0	0
Non Current Liabilities Total	144,170	157,221	104,702	99,477	86,870	59,481	58,246	16,919	18,677	17,021	6,749	4,314	200	200	11,508	15,958	10,072	0
Non Currrent Assets Other	4,670	4,770	4,067	2,107	2,840	6,697	6,006	27	27	299	162	-12,713	400	0	0	0	0	0
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	4,770	4,067	6,366	2,840	6,697	6,832	27	27	298	163	828	0	-1,500	0	0	0	0
Other Current Assets	5,334	5,095	4,339	3,046	2,534	1,766	2,051	314	111	144	299	108	0	100	0	0	0	0
Other Current Liab	32,919	24,989	17,215	8,365	4,481	3,552	58	2,385	1,968	2,329	860	747	10	-788	11,508	15,958	10,072	0
Other Liab	0	3,683	2,373	2,173,584	2,368	18,047	18,035	4,598	4,394	2,064	1,686	356	0	0	0	0	0	0
Other Stockholder Equity	641,439	629,969	553,266	428,704	290,904	239,624	192,308	104,700	89,993	76,741	75,245	46,533	139	613	-3,070	-13,561	4,580	0
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Gross	90,207	58,261	50,935	45,852	31,741	30,116	30,467	2,001	2,397	2,841	765	779	900	1,100	0	0	0	0
Property Plant And Equipment Net	63,470	68,747	58,198	45,852	31,741	30,116	30,467	2,001	2,397	2,841	765	779	0	1,100	0	0	0	0
Property Plant Equipment	0	58,261	50,935	45,852,281	31,741	30,116	30,467	2,001	2,397	2,841	765	779	0	0	0	0	0	0
Retained Earnings	-506,256	-478,017	-412,113	-340,465	-264,717	-216,437	-150,694	-106,935	-87,420	-69,450	-52,637	-37,109	-140	-114	-114	0	0	0
Retained Earnings Total Equity	0	-478,017	-412,113	-340,465	-264,717	-216,437	-150,694	-106,935	-87,420	-69,450	-52,637	-37,109	0	0	0	0	0	0
Short Long Term Debt	0	0	0	0	0	0	40,211	6,111	15	14	0	0	0	0	0	0	0	0
Short Long Term Debt Total	141,418	154,443	102,920	97,669	84,731	44,224	42,971	20,259	15,731	14,970	5,076	3,969	9,818	7,200	11,508	15,958	10,072	10,072
Short Term Debt	1,045	905	591	366	229	30	3,318	6,128	15	14	13	12	0	0	0	0	0	0
Short Term Investments	0	0	0	0	0	0	1,500	5,390	6,368	4,653	2,935	0	0	0	0	0	0	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	329,182	348,462	276,253	207,673	127,091	88,877	108,019	23,685	23,715	27,227	31,980	15,555	9	12	8,688	2,647	14,652	14,652
Total Current Assets	257,013	270,402	208,729	153,741	85,820	44,530	63,167	21,657	21,290	24,088	31,052	13,948	9	12	8,688	2,647	14,652	14,652
Total Current Liabilities	49,806	39,267	30,378	19,947	14,028	9,625	9,440	11,223	4,217	4,198	3,658	1,817	10	12	11,508	15,958	10,072	10,072
Total Liab	193,976	196,488	135,080	119,424	100,898	69,106	67,686	28,142	22,894	21,219	10,407	6,132	10	12	8,688	2,647	14,652	14,652
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	135,206	151,974	141,173	88,249	26,193	19,770	40,333	-4,457	821	6,009	21,573	9,424	-1	0	-2,820	-13,311	4,580	0
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30
Accounts Payable	15,660	10,851	12,085	12,956	13,229	25,198	11,388	14,115	12,429	17,283	6,167	12,153	11,074	7,980	6,910	9,152	9,175	8,960	6,788	5,480	5,900	5,268	3,101	5,718	5,921	9,156	4,672	3,904	2,565	2,777	3,317	2,468	2,088	2,185	1,648	1,779	1,779	2,445	2,340	2,764	2,709	1,483	1,159	1,379	1,059	891	791	509	5	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Accumulated Other Comprehensive Income	0	0	0	0	0	0	0	0	0	0	0	0	0	-7,889	-7,038	-6,333	-5,725	-5,271	-4,671	-4,079	-3,421	-2,880	-2,338	-1,803	-1,286	-819	-359	0	-2,223	0	0	-1,754	-1,754	0	0	-1,284	-1,284	0	0	-1,036	-1,036	0	0	-825	-825	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Lease Obligations	10,824	10,948	11,201	11,424	11,610	11,357	11,451	7,938	8,053	7,417	7,459	6,737	4,700	2,861	2,937	1,832	1,302	1,356	1,415	1,461	119	127	134	0	0	0	0	15	20	24	28	32	36	40	44	48	51	55	58	62	65	69	72	75	78	81	84	87	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Stock	23	23	22	22	22	20	20	20	20	14	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Surpluse	0	0	637,916	630,438	629,969	566,150	565,266	564,034	553,266	498,230	489,331	471,337	428,704	392,424	381,011	380,289	290,904	290,268	289,617	239,540	236,203	235,601	235,018	191,537	191,022	150,701	150,188	102,712	102,476	102,222	101,959	88,662	88,240	87,750	87,253	86,485	75,457	75,130	74,803	74,443	74,209	47,199	46,974	46,751	46,533	46,464	46,263	46,151	156	141	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Cash	51,352	74,157	62,513	69,204	86,522	34,906	52,415	69,505	51,089	34,411	42,409	61,966	55,921	59,675	75,781	101,236	26,752	48,006	73,616	16,534	22,755	42,367	55,154	26,120	43,108	13,601	25,574	8,543	9,915	7,906	12,549	8,925	10,441	9,178	7,822	16,564	17,199	13,952	17,869	26,518	26,149	5,380	7,653	10,321	12,536	10,720	12,888	14,240	8	6	9	16	3	3,619	12	2,934	6,844	9,270	8,688	10,108	8,028	2,647	2,647	6,569	8,787	7,805	14,652	16,663	9,033	11,253
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Cash And Short Term Investments	51,352	74,157	62,513	69,204	86,522	34,906	52,415	69,505	51,089	34,411	42,409	61,966	55,921	59,675	75,781	101,236	26,752	48,006	73,616	16,534	22,755	42,367	55,154	26,120	43,108	13,601	25,574	8,788	15,305	18,933	23,820	11,620	16,809	20,942	23,752	28,076	21,852	20,271	24,183	28,721	29,085	5,380	7,653	10,321	12,536	10,720	12,888	14,240	8	6	9	16	3	3,619	12	2,934	6,844	9,270	8,688	10,108	8,028	0	2,647	6,569	8,787	7,805	14,652	16,663	9,033	11,253
Common Stock	23	23	22	22	22	20	20	20	20	14	13	12	10	9	9	9	6	6	6	5	5	5	5	5	5	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	5	5	0	0	0	0	0	250	0	250	250	250	250	250	250	0	250	0	0	0	0	0	0	-
Common Stock Shares Outstanding	225,968	233,761	222,683	221,922	202,830	196,384	196,353	195,872	180,814	133,770	127,416	115,662	96,620	87,698	86,347	73,782	59,318	59,318	52,206	46,353	46,353	46,350	42,712	45,317	45,317	25,791	16,427	12,887	12,887	12,887	12,122	10,711	10,711	10,708	10,706	9,855	9,855	9,292	9,292	9,292	9,292	5,871	5,871	5,871	4,654	5,911	5,911	3,363	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500,000	2,500	2,500,000	2,500,000	2,500,000	2,500,000	2,500,000	2,500,000	2,500
Common Stock Total Equity	0	0	22	22	22	20	20	20	20	14	13	12	10	9	9	9	6	6	6	5	5	5	5	5	5	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	5	5	0	0	0	0	0	250	0	250	250	250	250	250	250	250	250	0	0	0	0	0	0	-
Current Deferred Revenue	182	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	1,198	143	143	143	143	143	143	143	145	145	145	145	145	145	145	145	149	76	76	76	76	76	76	76	76	69	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	38	18	181	272	307	323	308	150	282	203	245	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	0	0	2,154	2,190	2,226	2,262	2,297	2,333	2,369	2,404	2,440	2,476	2,511	2,547	2,583	2,619	2,745	2,788	2,831	2,875	2,918	2,962	3,023	1,611	1,638	2,065	1,876	1,886	1,876	1,686	1,879	1,913	315	128	133	139	144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Good Will	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	3,530	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Intangible Assets	499	477	656	835	1,013	1,192	1,371	1,550	1,729	1,908	2,086	2,265	2,444	2,623	2,802	2,981	3,159	3,371	3,582	3,793	4,004	4,216	4,427	4,638	4,849	5,737	6,011	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Inventory	172,906	163,116	161,780	163,985	163,280	162,914	146,075	139,146	124,724	114,123	99,700	94,146	81,536	69,753	56,001	52,289	53,065	40,285	23,590	18,440	18,616	13,877	12,247	12,439	12,628	13,419	13,151	5,308	5,020	4,618	4,209	4,049	3,446	2,831	2,453	1,941	1,709	1,453	1,113	984	1,669	1,205	915	1,007	1,266	1,010	1,203	1,175	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Liabilities And Stockholders Equity	329,182	348,997	343,027	340,788	348,462	300,558	296,932	308,032	276,253	238,640	232,814	235,667	207,673	189,976	191,542	210,524	127,091	137,780	143,274	78,120	88,877	106,345	117,752	91,138	108,019	72,813	84,639	17,595	23,685	27,495	31,742	19,685	23,715	27,824	29,800	33,928	27,227	25,287	27,883	31,951	31,980	8,702	10,690	13,817	15,555	13,225	15,884	17,008	8	6	9	16	3	3,619	12	2,934	6,844	9,270	8,688	10,108	8,028	-10,664	2,647	6,569	8,787	7,805	14,652	16,663	9,033	11,253
Long Term Debt	130,594	142,026	140,312	144,301	142,833	141,366	139,811	138,423	94,866	94,363	93,877	93,413	92,969	97,044	96,574	96,129	68,291	82,738	82,359	40,885	29,201	28,914	28,638	28,377	28,128	16,324	11,151	10,845	12,322	13,794	18,050	14,381	14,247	14,116	13,993	14,893	14,772	9,860	9,707	9,674	4,865	4,841	4,817	4,794	3,774	81	84	87	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Long Term Debt Total	0	0	0	0	0	0	0	0	0	0	0	0	0	99,904	99,511	97,961	69,594	84,095	83,774	42,347	29,320	29,040	28,772	28,377	28,128	16,324	11,151	10,861	12,341	13,818	18,078	14,413	14,283	14,156	14,037	14,940	14,824	9,915	9,765	9,736	4,930	4,909	4,888	4,869	3,851	81	84	87	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Long Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Debt	90,066	78,817	89,001	86,521	67,921	117,817	98,846	76,856	51,831	67,369	58,927	38,184	41,748	40,505	23,941	-3,081	57,979	36,318	10,382	40,904	21,469	1,568	-11,495	17,107	-137	17,558	7,071	10,791	10,344	12,163	7,335	6,935	5,290	6,425	7,662	-1,477	-2,229	-3,891	-7,958	-16,636	-21,074	-326	-2,621	-5,307	-8,567	-10,629	-12,794	-14,143	-8	-6	9,809	5,802	4,815	4,989	12,346	3,774	-1,036	638	2,820	-3,250	-570	13,311	13,311	4,489	-378	703	-4,580	-13,091	-5,167	-7,637
Net Invested Capital	265,800	293,463	287,074	289,956	294,807	241,750	254,211	265,356	236,039	197,143	205,471	205,917	181,218	168,420	173,453	192,465	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Receivables	27,421	31,319	36,732	26,518	15,505	20,902	18,884	25,630	28,577	20,393	23,545	15,362	13,237	6,335	6,514	7,108	3,470	7,315	5,087	1,310	1,392	4,127	3,797	3,658	3,880	1,500	2,292	840	1,018	1,328	827	944	924	1,201	522	351	384	562	804	484	0	335	237	326	39	62	220	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Tangible Assets	0	0	146,762	145,655	151,974	100,385	114,401	126,933	141,173	102,780	105,978	112,504	82,275,796	65,223	70,548	89,826	19,504	29,218	39,794	2,716	12,237	29,461	43,803	14,858	31,954	3,726	18,141	-10,758	-4,457	-152	3,916	-3,369	821	4,914	9,520	13,430	6,009	9,245	12,303	15,904	21,573	-736	1,728	6,401	9,424	11,607	14,656	15,750	3	-4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Working Capital	207,207	231,858	224,291	227,358	231,135	179,654	194,703	208,234	178,351	142,448	153,169	156,071	133,793	123,075	130,110	151,580	71,792	82,173	93,760	29,996	34,905	52,610	66,712	36,977	53,726	18,105	28,626	2,725	10,434	16,152	24,412	13,067	17,074	20,942	23,927	27,195	19,890	18,453	22,697	26,484	27,395	4,627	7,144	10,205	12,131	10,578	13,613	14,817	3	-4	-1	10	-2	-4,989	0	-3,774	1,036	-638	-2,820	3,250	570	-13,311	-13,311	-4,489	378	-703	4,580	13,091	5,167	-
Non Current Assets Total	72,169	75,298	76,784	76,701	78,060	76,463	74,158	68,232	67,523	63,855	61,459	58,390	53,933	50,428	48,552	45,036	41,270	40,456	39,385	39,786	44,347	43,842	44,122	44,718	44,852	41,369	40,368	1,912	2,028	2,136	2,248	2,327	2,424	2,584	2,673	2,946	3,139	2,716	1,389	1,164	927	1,558	1,518	1,512	1,607	1,243	1,265	1,165	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Current Liabilities Other	2,107	2,002	2,017	1,839	1,850	1,862	1,874	1,886	397	233	36	42	55	68	81	94	15,015	119	132	15,028	27,757	27,766	27,828	27,781	27,570	27,575	27,543	1,790	1,790	1,790	1,790	1,432	1,432	1,432	1,432	133	133	133	133	133	133	133	133	133	335	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Current Liabilities Total	144,170	155,718	154,312	158,405	157,221	155,733	154,460	149,533	104,702	103,523	103,034	101,957	99,477	102,127	101,782	100,280	86,870	86,512	86,240	59,743	59,481	59,246	59,076	58,669	58,246	46,482	41,312	15,395	16,919	18,440	22,743	18,763	18,677	18,612	17,080	16,710	17,021	11,924	11,784	11,744	6,749	6,921	6,933	5,316	4,314	214	222	231	0	0	0	0	0	8,608	0	6,708	5,808	9,908	11,508	6,858	7,458	15,958	15,958	11,058	8,409	8,508	10,072	3,572	3,866	3,616
Non Currrent Assets Other	4,670	6,723	6,289	4,719	4,770	4,459	3,756	2,826	4,067	3,334	2,527	2,223	2,107	1,870	4,847	3,465	2,840	2,843	2,829	2,768	6,697	5,735	5,829	5,935	6,006	2,347	2,201	30	27	27	27	31	27	65	45	208	299	334	350	335	162	747	668	710	828	440	440	350	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Assets	0	0	6,289	0	4,770	4,459	3,756	2,826	4,067	3,334	2,527	2,223	6,366	4,653	4,847	3,465	2,840	2,843	2,829	2,768	6,697	5,735	5,829	5,935	14,385	11,614	11,742	30	27	27	27	31	28	65	45	208	298	334	350	335	163	747	668	709	828	439	440	349	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Current Assets	5,334	5,107	5,219	4,379	5,095	5,372	5,400	5,519	4,339	5,859	5,702	5,803	3,046	3,786	4,693	4,855	2,534	1,716	1,597	2,050	1,766	2,131	2,431	2,703	2,051	2,079	2,408	747	314	482	638	745	111	267	399	613	144	286	395	598	299	223	367	651	108	190	308	428	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Current Liab	32,919	29,864	28,746	22,672	24,989	18,379	15,961	16,655	17,215	14,410	11,490	8,592	8,365	8,075	5,617	4,419	4,481	4,763	2,974	2,506	3,552	4,453	3,644	3,582	58	177	4,161	2,225	2,385	1,825	1,605	1,662	1,968	1,949	1,463	1,918	2,329	1,585	1,368	1,451	860	947	789	710	747	503	205	508	5	10	10	6	5	8,608	12	6,708	5,808	9,908	11,508	6,858	7,458	0	15,958	11,058	8,409	8,508	10,072	3,572	3,866	3,616
Other Liab	0	0	3,778	0	3,683	3,731	3,778	3,826	2,373	2,244	2,083	2,125	2,173,584	2,222	2,271	2,319	2,368	2,417	2,465	2,514	18,047	18,100	18,206	18,203	15,275	2,701	2,712	2,744	2,787	2,832	2,875	2,918	2,962	3,024	1,610	1,637	2,064	1,876	1,886	1,875	1,686	1,878	1,911	313	356	133	138	144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Stockholder Equity	641,439	640,026	637,916	630,438	629,969	566,150	565,266	564,034	553,266	498,230	489,331	471,337	428,704	392,424	381,011	380,289	296,629	295,539	294,288	243,619	239,624	238,481	237,356	193,340	192,308	151,520	150,547	102,712	104,700	102,222	101,959	88,662	89,993	87,750	87,253	86,485	76,741	75,130	74,803	74,443	75,245	47,199	46,974	46,751	46,533	46,464	46,263	46,151	156	141	139	139	122	-5,121	113	-4,024	786	-888	-3,070	3,000	320	0	-13,561	-4,489	378	-703	4,580	13,091	5,205	7,670
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Property Plant And Equipment Gross	90,207	89,684	56,306	57,371	58,261	56,946	54,951	53,220	50,935	48,394	53,316	50,373	45,852	42,405	37,373	35,061	31,741	30,713	29,444	29,695	30,116	30,363	30,337	30,616	30,467	29,756	28,627	1,882	2,001	2,109	2,221	2,296	2,397	2,519	2,628	2,738	2,841	2,381	1,039	829	765	811	850	802	779	804	825	815	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Property Plant And Equipment Net	63,470	64,568	66,309	67,618	68,747	67,282	65,502	60,327	58,198	55,085	53,316	50,373	45,852	42,405	37,373	35,061	31,741	30,713	29,444	29,695	30,116	30,363	30,337	30,616	30,467	29,756	28,627	1,882	2,001	2,109	2,221	2,296	2,397	2,519	2,628	2,738	2,841	2,381	1,039	829	765	811	850	802	779	804	825	815	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Property Plant Equipment	0	0	56,306	57,371	58,261	56,946	54,951	53,220	50,935	48,394	53,316	44,176	45,852,281	39,623	37,373	35,061	31,741	30,713	29,444	29,695	30,116	30,363	30,337	30,616	30,467	29,756	28,627	1,882	2,001	2,109	2,221	2,296	2,397	2,519	2,628	2,738	2,841	2,381	1,039	829	765	811	850	802	779	804	825	815	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Retained Earnings	-506,256	-488,611	-491,176	-484,805	-478,017	-465,785	-450,885	-437,121	-412,113	-395,463	-377,750	-358,845	-340,465	-321,057	-304,140	-283,962	-264,717	-254,156	-242,717	-229,505	-216,437	-198,399	-183,264	-168,516	-150,694	-137,711	-122,508	-113,472	-106,935	-102,376	-98,044	-92,032	-87,420	-82,837	-77,735	-73,055	-69,450	-65,886	-62,502	-58,540	-52,637	-47,935	-45,246	-40,351	-37,109	-34,858	-31,612	-30,405	-154	-145	-140	-128	-123	-118	-114	0	0	0	0	0	0	0	0	0	0	0	0	0	-38	-33
Retained Earnings Total Equity	0	0	-491,176	-484,805	-478,017	-465,785	-450,885	-437,121	-412,113	-395,463	-377,750	-358,845	-340,465	-321,057	-304,140	-283,962	-264,717	-254,156	-242,717	-229,505	-216,437	-198,399	-183,264	-168,516	-150,694	-137,711	-122,508	-113,472	-106,935	-102,376	-98,044	-92,032	-87,420	-82,837	-77,735	-73,055	-69,450	-65,886	-62,502	-58,540	-52,637	-47,935	-45,246	-40,351	-37,109	-34,858	-31,612	-30,405	-154	-145	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Short Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	210	0	0	40,899	40,467	40,211	29,369	30,855	17,544	6,111	0	0	0	15	0	0	0	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Short Long Term Debt Total	141,418	152,974	151,514	155,725	154,443	152,723	151,261	146,361	102,920	101,780	101,336	100,150	97,669	100,180	99,722	98,155	84,731	84,324	83,997	57,438	44,224	43,936	43,659	43,227	42,971	31,159	32,645	19,334	20,259	20,069	19,884	15,860	15,731	15,603	15,484	15,087	14,970	10,061	9,911	9,881	5,076	5,054	5,033	5,013	3,969	91	94	97	5,306	9,809	9,818	5,818	4,818	8,608	12,358	6,708	5,808	9,908	11,508	6,858	7,458	15,958	15,958	11,058	8,409	8,508	10,072	3,572	3,866	3,616
Short Term Debt	1,045	983	980	956	905	721	580	654	591	501	386	318	366	276	211	194	229	230	223	210	30	29	29	40,467	3,318	3,860	6,667	6,684	6,128	4,461	16	15	15	15	14	14	14	14	13	13	13	12	12	12	12	10	10	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Short Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,500	1,500	0	0	245	5,390	11,027	11,271	2,695	6,368	11,764	15,930	11,512	4,653	6,320	6,314	2,203	2,935	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Assets	329,182	348,997	343,027	340,788	348,462	300,558	296,932	308,032	276,253	238,640	232,814	235,667	207,673	189,976	191,542	210,524	127,091	137,780	143,274	78,120	88,877	106,345	117,752	91,138	108,019	72,813	84,639	17,595	23,685	27,495	31,742	19,685	23,715	27,824	29,800	33,928	27,227	25,287	27,883	31,951	31,980	8,702	10,690	13,817	15,555	13,225	15,884	17,008	8	6	9	16	3	3,619	12	2,934	6,844	9,270	8,688	10,108	8,028	2,647	2,647	6,569	8,787	7,805	14,652	16,663	9,033	11,253
Total Current Assets	257,013	273,699	266,243	264,086	270,402	224,095	222,774	239,800	208,729	174,785	171,355	177,277	153,741	139,549	142,990	165,488	85,820	97,323	103,889	38,334	44,530	62,503	73,630	46,419	63,167	31,444	44,271	15,683	21,657	25,360	29,494	17,358	21,290	25,240	27,127	30,982	24,088	22,572	26,494	30,788	31,052	7,144	9,173	12,306	13,948	11,982	14,619	15,844	8	6	9	16	3	3,619	12	2,934	6,844	9,270	8,688	10,108	8,028	2,647	2,647	6,569	8,787	7,805	14,652	16,663	9,033	11,253
Total Current Liabilities	49,806	41,841	41,952	36,728	39,267	44,440	28,072	31,567	30,378	32,337	18,186	21,206	19,947	16,474	12,880	13,908	14,028	15,150	10,129	8,338	9,625	9,893	6,917	9,443	9,440	13,339	15,645	12,958	11,223	9,208	5,083	4,291	4,217	4,298	3,200	3,787	4,198	4,119	3,797	4,303	3,658	2,517	2,029	2,101	1,817	1,404	1,006	1,027	5	10	10	6	5	8,608	12	6,708	5,808	9,908	11,508	6,858	7,458	15,958	15,958	11,058	8,409	8,508	10,072	3,572	3,866	3,616
Total Liab	193,976	197,559	196,265	195,133	196,488	200,173	182,532	181,099	135,080	135,860	121,220	123,163	119,424	118,600	114,662	114,188	100,898	101,662	96,368	68,081	69,106	69,139	65,993	68,112	67,686	59,821	56,957	28,353	28,142	27,648	27,826	23,054	22,894	22,910	20,280	20,497	21,219	16,042	15,580	16,048	10,407	9,438	8,962	7,417	6,132	1,618	1,228	1,258	5	10	10	6	5	3,619	12	2,934	6,844	9,270	8,688	10,108	8,028	2,647	2,647	6,569	8,787	7,805	14,652	16,663	9,033	11,253
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Stockholder Equity	135,206	151,437	146,762	145,655	151,974	100,385	114,401	126,933	141,173	102,780	111,594	112,504	88,249	71,376	76,879	96,336	26,193	36,118	46,906	10,039	19,770	37,206	51,759	23,025	40,333	12,993	27,682	-10,758	-4,457	-152	3,916	-3,369	821	4,914	9,520	13,430	6,009	9,245	12,303	15,904	21,573	-736	1,728	6,401	9,424	11,607	14,656	15,750	3	-4	-1	10	-2	-4,989	0	-3,774	1,036	-638	-2,820	3,250	570	0	-13,311	-4,489	378	-703	4,580	13,091	5,167	7,637
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Begin Period Cash Flow	86,522	51,089	55,921	26,752	26,755	48,608	9,915	10,441	17,199	26,149	12,536	88	12	9	2,647	14,652	25,767	25,767
Capital Expenditures	4,981	13,911	13,511	12,727	3,812	2,096	2,676	73	26	2,323	197	119	0	0	0	0	0	0
Cash And Cash Equivalents Changes	0	35,432	-4,832	29,169	-3	-21,853	38,693	-526	-6,758	-8,950	13,614	12,448	0	0	0	0	0	0
Cash Flows Other Operating	0	-633	-3,068	-710	-2,230	-749	-403	-233	78	118	380	-186	0	0	0	0	0	0
Change In Cash	-35,170	35,432	-4,832	29,169	-3	-21,853	38,693	-526	-6,758	-8,950	13,614	12,448	-4	3	6,041	-12,005	-11,115	-11,115
Change In Working Capital	-10,123	-18,285	-51,680	-33,781	-33,503	-3,688	-282	-1,008	-671	178	3,438	-437	-3	1	10,491	-17,891	4,580	0
Change Receivables	0	13,072	-15,340	-9,767	-2,077	2,488	-2,862	-94	-541	-384	39	-39	0	0	0	0	0	0
Change To Account Receivables	-11,916	13,072	-15,340	-9,767	-2,077	2,488	-2,862	-94	-541	-384	39	-39	0	0	0	0	0	0
Change To Inventory	-9,626	-38,556	-43,188	-28,471	-34,650	-5,988	589	-1,574	-1,737	-40	-403	-118	2,300	0	0	0	0	0
Change To Liabilities	0	7,832	9,916	1,899	3,890	561	3,415	894	1,528	483	3,422	-94	0	0	0	0	0	0
Change To Netincome	0	15,309	3,709	1,802	2,858	2,345	2,417	1,250	2,487	1,499	845	647	0	0	0	0	0	0
Change To Operating Activities	0	6,399	5,492	2,558	-49	-168	-821	184	-122	1,539	0	0	0	0	0	0	0	0
Depreciation	8,332	7,113	5,496	3,942	3,258	3,446	2,692	470	470	248	211	182	220	220	0	0	0	0
Dividends Paid	0	2,899	62	0	0	0	0	0	0	0	0	3,906	0	0	0	0	0	0
End Period Cash Flow	51,352	86,522	51,089	55,921	26,752	26,755	48,608	9,915	10,441	17,199	26,149	12,536	9	12	8,688	2,647	14,652	14,652
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	3,819	-73,419	-125,880	-114,730	-80,005	-64,774	-39,948	-18,342	-15,444	-17,028	-11,084	-7,023	-29	-20	-24,459	-19,005	-23,615	-23,615
Investments	-7,322	-13,911	-13,511	-12,725	-3,812	-2,096	5,390	978	-1,716	-1,717	-2,935	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	64,645	121,144	131,195	48,397	42,945	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	48,967	-34	13,518	34,290	-36	23,333	-62	-15,543	9,807	988	3,671	0	0	0	0	0	0
Net Income	-28,239	-65,904	-71,648	-75,749	-48,279	-65,743	-43,759	-19,515	-17,970	-16,813	-15,527	-7,301	-26	-21	-20,009	-24,891	-29,687	-29,687
Other Cashflows From Financing Activities	-1,415	150,041	62	26,683	61,636	13	41,567	2,708	15,459	9,808	614	6,449	26	23	30,500	7,000	12,500	0
Other Cashflows From Investing Activities	0	0	0	2	0	0	12,500	978	-1,716	0	0	0	0	0	0	0	0	0
Other Non Cash Items	14,940	12,353	1,755	1,640	1,038	961	639	534	391	360	147	7	1,610	-220	-14,941	23,777	1,492	0
Sale Purchase Of Stock	0	-2,899	-62	131,209	48,472	42,958	39,207	12,901	10,307	-12	-26,518	-150	0	0	0	0	0	0
Stock Based Compensation	6,187	5,215	3,488	2,855	2,651	2,223	1,562	1,250	1,711	1,248	888	627	0	0	0	0	0	0
Total Cash From Financing Activities	-38,989	108,852	121,048	143,897	80,003	42,922	60,751	16,838	10,402	9,795	27,633	19,471	26	23	30,500	7,000	12,500	12,500
Total Cash From Operating Activities	8,800	-59,508	-112,369	-102,003	-76,194	-62,679	-37,272	-18,269	-15,418	-14,705	-10,887	-6,904	-29	-20	-24,459	-19,005	-23,615	-23,615
Total Cashflows From Investing Activities	0	-13,911	-13,511	-12,725	-3,812	-2,096	15,214	905	-1,742	-4,041	-3,132	-119	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31
Begin Period Cash Flow	74,157	62,513	69,204	86,522	34,906	52,415	69,505	51,089	34,411	42,409	61,966	55,921	59,675	75,781	101,236	26,752	48,006	73,616	16,534	26,755	46,367	59,154	31,620	48,608	13,601	25,574	8,543	9,915	7,906	12,549	8,925	10,441	9,178	7,822	16,564	17,199	13,952	17,869	26,518	26,149	5,380	7,653	10,321	12,536	10,720	12,888	14,240	88	6	9	16	3	4	12	3	7	9,270	8,688	10,108	8,028	2,647	2,647	-431	0	7,805	14,652	16,663	9,033	11,253
Capital Expenditures	1,407	757	873	1,945	3,749	3,380	3,940	2,842	3,676	2,789	4,476	2,571	3,598	2,885	4,168	2,075	1,594	1,972	135	110	819	230	497	549	2,010	570	93	4	10	5	41	17	4	9	8	14	556	1,396	259	112	5	16	109	66	35	27	56	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Cash Equivalents Changes	0	0	-6,691	-17,317	51,616	-17,509	-17,090	18,416	16,679	-7,998	-19,557	6,045	-3,754	-16,106	-25,455	74,484	-21,254	-25,610	57,082	-10,221	-19,613	-12,786	27,534	-16,988	35,006	-11,973	17,031	-1,372	2,009	-4,643	3,624	-1,516	1,263	1,356	-8,742	-635	3,248	-3,918	-8,649	368	20,769	-2,273	-2,667	-2,215	1,815	-3,522	0	14,152	2	-3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	-2,166	1,006	204	-462	-594	218	558	-826	-64	-2,736	618	1,116	-42	-2,401	-2,379	-134	392	-109	-649	304	278	-682	1,290	82	-1,331	-443	160	149	99	-642	148	-594	925	-401	137	104	176	-298	380	-1,571	1,925	-354	51	138	0	-375	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-22,805	11,644	-6,691	-17,317	51,616	-17,509	-17,090	18,416	16,679	-7,998	-19,557	6,045	-3,754	-16,106	-25,455	74,484	-21,254	-25,610	57,082	-10,221	-19,613	-12,786	27,534	-16,988	35,006	-11,973	17,031	-1,372	2,009	-4,643	3,624	-1,516	1,263	1,356	-8,742	-635	3,248	-3,918	-8,649	368	20,769	-2,273	-2,667	-2,215	1,815	-2,167	-1,352	14,152	2	-3	-8	13	-1	-8	9	-4	-2,426	582	-1,420	2,080	5,381	-12,005	3,078	-2,218	-6,018	-6,847	-2,011	7,630	-2,220
Change In Working Capital	3,602	3,862	-5,060	-12,527	-3	-3,490	-3,334	-11,458	-20,155	1,738	-15,994	-17,269	-14,212	-9,188	-3,119	-7,262	-11,161	-14,022	-7,013	-1,306	-2,643	909	-1,778	-176	-4,408	3,976	-476	626	415	-885	656	-1,194	-175	1,767	-1,087	-1,176	99	424	-873	528	1,418	155	1,965	-100	159	887	10	-1,493	-5	0	4	1	-4	-4	6	1	1,674	2,182	-6,070	2,680	13,881	-8,822	-8,822	-4,867	1,081	-5,283	-8,511	7,924	5,167
Change Receivables	0	0	-10,213	-11,013	5,397	-2,019	6,746	2,947	-8,184	3,152	-8,183	-2,125	-6,903	180	594	-3,638	3,846	-2,229	-3,776	82	2,734	-330	-140	223	-2,380	792	-1,452	178	310	-501	117	-19	276	-678	-171	33	178	241	-319	-484	335	-98	89	-287	23	-62	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	3,898	5,413	-10,213	-11,013	5,397	-2,019	6,746	2,947	-8,184	3,152	-8,183	-2,125	-6,903	180	594	-3,638	3,846	-2,229	-3,776	82	2,734	-330	-140	223	-2,380	792	-1,452	178	310	-501	117	-19	276	-678	-171	33	178	241	-319	-484	335	-98	89	-287	23	158	-220	-665	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Inventory	-9,790	-1,336	2,205	-705	-366	-16,838	-6,929	-14,422	-10,601	-14,423	-5,554	-12,611	-11,783	-13,751	-3,713	776	-12,779	-16,696	-5,150	-25	-4,739	-1,630	192	189	791	-268	355	-288	-402	-408	-160	-603	-615	-378	-512	-232	-256	-340	-128	685	-464	-290	92	258	-256	193	-28	-28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	0	5,115	-1,814	-5,238	15,828	-2,557	-201	-1,927	13,835	-5,985	203	3,094	3,268	41	-1,999	-1,413	5,036	1,521	-1,254	10	2,565	-2,108	94	-3,087	3,370	1,953	1,179	348	-124	600	71	16	2,698	-610	-575	41	419	-602	626	1,167	2,113	-142	283	341	660	0	-1,091	-5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Netincome	0	0	2,623	2,108	2,461	2,298	2,237	8,313	1,354	691	847	782	-270	784	718	678	2,381	669	735	-927	705	588	538	515	1,360	506	311	240	254	263	311	422	489	1,167	437	393	414	392	444	248	239	222	202	182	239	362	0	46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	3,820	3,820	6,935	1,557	-424	-1,669	3,484	1,893	3,727	-3,613	1,380	3,314	2,242	-4,378	-1,387	1,675	604	-942	-1,272	702	787	-386	-821	-13	198	-604	184	0	0	0	-122	0	0	0	1,539	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	2,109	2,093	2,098	2,033	1,937	1,862	1,724	1,590	1,518	1,422	1,326	1,230	1,233	1,035	886	789	829	818	806	805	924	847	846	830	1,461	836	277	118	118	117	116	118	117	118	118	117	97	54	49	48	52	55	61	44	41	49	46	46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dividends Paid	0	0	247	0	2,068	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	51,352	74,157	62,513	69,204	86,522	34,906	52,415	69,505	51,089	34,411	42,409	61,966	55,921	59,675	75,781	101,236	26,752	48,006	73,616	16,534	26,755	46,367	59,154	31,620	48,608	13,601	25,574	8,543	9,915	7,906	12,549	8,925	10,441	9,178	7,822	16,564	17,199	13,952	17,869	26,518	26,149	5,380	7,653	10,321	12,536	10,720	12,888	14,240	8	6	9	16	3	4	12	3	6,844	9,270	8,688	10,108	8,028	2,647	2,647	-2,218	-6,018	7,805	14,652	16,663	9,033
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	16,189	11,229	-6,931	-16,667	-11,128	-16,665	-16,771	-28,855	-37,141	-16,201	-36,738	-35,800	-35,818	-26,737	-25,453	-26,722	-21,246	-25,602	-18,759	-14,398	-19,612	-12,774	-15,405	-16,983	-15,369	-10,309	-8,868	-5,402	-3,624	-4,689	-4,845	-5,185	-4,074	-2,682	-4,454	-4,235	-3,459	-3,862	-4,555	-5,152	-2,965	-2,242	-2,736	-3,141	-1,842	-2,129	-997	-1,999	-13	-5	-8	-4	-9	-8	-2	-4	-8,426	-5,418	-4,420	-4,420	3,386	-3,922	-3,922	-2,218	-6,018	-6,847	-2,011	-2,370	-4,720
Investments	-1,407	-757	-873	-1,945	-3,749	-3,380	-3,940	-2,842	-3,676	-2,789	-4,476	-2,571	-3,598	-2,885	-4,168	-2,073	-1,594	-1,972	-135	-110	0	0	0	0	5,390	0	245	5,145	5,637	244	-8,576	3,673	5,396	4,166	-4,418	-6,860	1,667	-6	-4,111	732	-2,935	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	64,645	0	0	0	53,828	8,214	17,190	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	-6	-6	-9	-405	-9	49,372	-9	-9	-9	-8	1,042	-8	8	12,492	-6,508	-8	27,369	13,437	-7	-18	-7	-4	12,965	-1,671	13,154	-1,115	-4	-27	-28	-4	-59	-15,812	332	-3	4,997	-3	25	4,789	-3	-3	-3	997	3,879	-5	0	-203	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-17,645	2,565	-6,371	-6,789	-12,232	-14,900	-13,765	-25,008	-16,649	-17,713	-18,905	-18,380	-19,408	-16,917	-20,178	-19,245	-10,561	-11,438	-13,212	-13,068	-18,038	-15,135	-14,748	-17,822	-12,983	-15,203	-9,036	-6,537	-4,559	-4,331	-6,012	-4,612	-4,583	-5,102	-4,679	-3,606	-3,563	-3,385	-3,961	-5,904	-4,701	-2,689	-4,895	-3,242	-2,252	-3,246	-1,207	-597	-8	-5	-12	-5	-5	-5	-8	-5	-4	-3,818	-20,009	-10,939	-7,119	-24,891	-24,891	-16,069	-11,202	-5,283	-29,687	-21,176	-19,100
Other Cashflows From Financing Activities	-340	-209	247	-641	2,243	-405	-310	147,280	-3,676	-2	-4,476	-59	14,170	-2,885	6	12,507	-48,397	-1,972	75,848	34,184	-42,939	6	42,946	-549	26,735	8	14,825	5,142	5,626	-1,267	3,976	3,656	-56	11	15,503	-6,874	5,043	-46	20	4,792	-358	-28	72	928	3,809	-36	-296	-934	15	3	0	17	9	6	11	0	-6,000	6,000	3,000	6,500	14,000	0	7,000	0	0	0	0	10,000	2,500
Other Cashflows From Investing Activities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	12,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	34,646	1,678	1,637	1,450	1,850	1,929	1,353	7,221	468	450	429	408	402	434	409	394	425	343	60	209	260	248	234	220	190	145	148	155	158	153	125	98	73	96	96	125	108	99	94	59	33	31	42	41	218	208	154	46	0	0	0	0	0	0	0	0	-10,096	-3,782	21,659	3,839	-3,376	0	29,791	18,718	4,103	3,719	36,187	10,882	9,213
Sale Purchase Of Stock	0	-209	-225	-641	-2,068	-430	-310	0	53,828	8,214	17,190	41,913	31,852	10,639	6	88,711	48,472	48,472	48,472	0	7	5	42,946	0	39,200	8	13,073	0	10,257	-172	13,073	0	0	-87	-70	10,463	43	-46	-9	0	26,673	43	0	-72	-150	-333	0	16,353	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	1,745	1,695	1,637	1,110	1,069	1,313	1,191	1,641	1,213	688	805	781	688	775	716	677	636	651	727	637	596	578	535	515	509	506	311	236	254	263	311	422	489	448	387	387	327	327	360	234	222	225	223	219	218	208	154	46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	-38,994	415	240	-651	62,743	-844	-319	47,271	53,820	8,203	17,181	41,845	32,064	10,631	-2	101,203	-8	-8	75,841	4,177	-1	-13	42,939	-4	50,375	-1,663	13,154	-1,115	-4	-199	17,045	-4	-59	-128	130	10,460	5,039	-49	16	4,789	26,670	-31	69	926	3,658	-39	-299	16,151	15	3	0	17	9	6	11	0	-6,000	6,000	3,000	6,500	14,000	7,000	7,000	0	0	0	0	10,000	2,500
Total Cash From Operating Activities	17,596	11,985	-6,059	-14,722	-7,379	-13,285	-12,831	-26,013	-33,465	-13,412	-32,262	-33,229	-32,219	-23,852	-21,284	-24,647	-19,652	-23,630	-18,624	-14,287	-18,793	-12,543	-14,908	-16,434	-13,359	-9,739	-8,775	-5,398	-3,614	-4,683	-4,804	-5,168	-4,078	-2,673	-4,446	-4,221	-2,902	-2,466	-4,296	-5,040	-2,960	-2,226	-2,627	-3,075	-1,807	-2,101	-997	-1,999	-13	-5	-8	-4	-9	-8	-2	-4	-8,426	-5,418	-4,420	-4,420	3,386	-3,922	-3,922	-2,218	-6,018	-6,847	-2,011	-2,370	-4,720
Total Cashflows From Investing Activities	0	0	-873	-1,945	-3,749	-3,380	-3,940	-2,842	-3,676	-2,789	-4,476	-2,571	-3,598	-2,885	-4,168	-2,073	-1,594	-1,972	-135	-110	-819	-230	-497	-549	-2,010	-570	12,652	5,142	5,626	239	-8,617	3,656	5,401	4,157	-4,426	-6,874	1,111	-1,403	-4,369	620	-2,941	-16	-109	-66	-35	-84	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cost Of Revenue	169,997	118,815	79,769	61,291	39,504	42,195	29,164	6,361	4,311	3,742	2,023	669	0	0	0	0	0	0
Depreciation And Amortization	8,332	126	498	875	1,418	3,446	1,235	470	470	248	211	182	0	0	0	0	0	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	21,632	-39,365	-58,374	-64,915	-41,424	-60,221	-38,418	-17,276	-15,476	-16,327	-14,952	-7,888	-26	-21	-20,009	-24,891	-29,687	-29,687
Ebitda	29,964	-39,239	-57,875	-64,040	-40,006	-56,774	-37,183	-16,806	-15,006	-16,079	-14,742	-7,706	-26	-21	-20,009	-24,891	-29,687	0
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	88,218	35,265	1,173	-19,072	-10,155	-25,209	-6,404	4,300	2,866	2,173	1,044	449	0	0	0	0	0	0
Income Before Tax	-28,239	-65,904	-71,648	-75,749	-48,279	-65,743	-43,759	-19,515	-17,970	-17,365	-15,527	-7,919	-26	-21	-20,009	-24,891	-29,687	-29,687
Income Tax Expense	0	19,279	12,805	11,857	8,766	5,455	4,449	2,185	2,456	-552	485	-618	0	0	0	0	0	0
Interest Expense	25,027	19,279	13,057	11,985	8,993	5,523	3,286	2,240	1,843	1,286	618	31	0	0	0	0	0	0
Interest Income	1,007	45	35	288	801	195	57	50	1,737	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-28,239	-85,183	-84,453	-87,605	-57,045	-65,743	-43,759	-19,515	-17,970	-16,813	-15,527	-7,301	-26	-21	-20,009	-24,891	-29,687	-29,687
Net Income Applicable To Common Shares	0	-65,904	-71,648	-75,749	-48,279	-65,743	-43,759	-19,515	-17,970	-16,813	-15,527	-7,301	0	0	0	0	0	0
Net Income From Continuing Ops	-22,826	-65,904	-71,648	-75,749	-48,279	-65,743	-43,759	-19,515	-17,970	-16,813	-15,527	-7,301	0	0	0	0	0	0
Net Interest Income	-23,542	-19,235	-13,022	-11,697	-8,193	-5,327	-3,229	-2,189	0	0	0	0	0	0	0	0	0	0
Non Operating Income Net Other	0	-7,259	-217	1,151	2,138	68	-1,163	55	-613	-60	133	21	0	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	845	845	845	0	0	0	0	0	0	0	0	0
Operating Income	21,632	-39,365	-58,374	-64,915	-41,424	-60,289	-39,310	-17,330	-15,514	-16,019	-15,042	-7,909	-26	-21	-20,009	-24,891	-29,687	-29,687
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	236,583	193,445	139,316	107,135	70,773	77,274	61,225	27,991	22,691	21,934	18,110	9,027	26	21	20,009	24,916	29,735	29,735
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reconciled Depreciation	8,160	7,113	5,496	3,942	3,258	3,446	2,692	0	0	0	0	0	0	0	0	0	0	0
Research Development	3,300	3,614	3,646	5,907	2,344	3,926	6,230	7,688	7,016	9,517	9,303	3,469	0	0	0	0	0	0
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling General Administrative	57,380	70,301	55,186	35,051	25,911	22,503	18,093	8,495	6,746	4,824	4,365	3,142	26	21	21	0	24	0
Tax Provision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Operating Expenses	66,586	74,630	59,547	45,843	31,269	35,080	32,061	21,631	18,380	18,192	16,087	8,358	26	21	-20,009	24,916	29,735	29,735
Total Other Income Expense Net	-49,871	-26,539	-13,274	-10,834	-6,855	-127	-2,066	4	-651	-74	126	-1,747	0	0	0	0	0	0
Total Revenue	258,215	154,080	80,943	42,220	29,349	16,985	22,761	10,661	7,178	5,916	3,068	1,118	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30
Cost Of Revenue	43,005	42,622	43,433	40,401	35,804	31,433	26,136	25,441	22,871	20,295	18,833	17,770	19,111	11,855	13,496	16,829	11,692	7,916	10,491	9,405	11,142	9,164	9,646	12,243	11,923	11,291	4,334	1,616	2,014	1,736	1,344	1,266	1,503	1,113	786	910	957	868	941	977	282	726	486	529	380	145	142	1,172	4	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Depreciation And Amortization	2,109	2,093	2,098	319	-257	1,860	1,707	1,456	179	1,422	1,326	1,230	179	1,035	886	789	211	818	806	805	924	847	846	830	1,461	836	277	118	118	117	116	118	117	118	118	117	97	54	49	48	52	55	61	44	41	49	46	46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Ebit	14,233	8,963	-72	-813	-6,059	-9,317	-9,175	-14,815	-13,334	-14,414	-15,659	-15,184	-17,290	-13,826	-17,111	-16,528	-7,830	-8,789	-11,139	-13,092	-16,600	-13,733	-13,389	-16,499	-11,741	-14,420	-8,394	-5,918	-3,931	-3,725	-5,474	-4,145	-4,119	-4,653	-3,507	-3,197	-3,734	-3,035	-3,584	-5,682	-4,516	-2,529	-4,758	-3,150	-3,547	-2,273	-824	-745	-8	-5	-12	-5	-5	-5	-8	-5	-4	-3,818	-20,009	-10,939	-7,119	0	-24,891	-16,069	-11,202	-5,283	-29,687	-21,176	-19,100	-
Ebitda	16,342	11,055	2,026	-494	-6,316	-7,457	-7,468	-13,359	-13,155	-12,992	-14,333	-13,955	-17,111	-12,791	-16,225	-15,739	-7,619	-7,971	-10,333	-12,287	-15,676	-12,886	-12,543	-15,669	-10,280	-13,584	-8,117	-5,800	-3,813	-3,608	-5,358	-4,027	-4,002	-4,535	-3,389	-3,080	-3,637	-2,981	-3,535	-5,634	-4,465	-2,474	-4,697	-3,106	-3,506	-2,224	-778	-699	-8	-5	-12	-5	-5	-5	-8	-5	-4	-3,818	-20,009	-10,939	-7,119	-24,891	-24,891	-16,069	-11,202	-5,283	-29,687	-21,176	-19,100	-14
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Gross Profit	30,899	24,653	16,690	16,513	14,177	9,657	7,769	3,662	3,511	385	-1,002	-1,722	-5,155	-1,579	-5,708	-6,629	345	-694	-3,930	-5,877	-7,086	-4,934	-4,989	-8,201	80	-6,562	-935	1,013	1,313	1,202	928	857	1,009	740	524	593	532	498	560	584	142	381	258	264	143	216	88	4	-4	-1	0	-1	-1	-1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Income Before Tax	-17,645	2,565	-6,371	-6,789	-12,232	-14,900	-13,765	-25,008	-16,649	-17,713	-18,905	-18,380	-19,408	-16,917	-20,178	-19,245	-10,561	-11,438	-13,212	-13,068	-18,038	-15,135	-14,748	-17,822	-12,983	-15,203	-9,036	-6,537	-4,559	-4,331	-6,012	-4,612	-4,583	-5,102	-4,679	-3,606	-4,115	-3,385	-3,961	-5,904	-4,701	-2,689	-4,895	-3,242	-2,252	-3,246	-1,207	-1,215	-8	-5	-12	-5	-5	-5	-8	-5	-4	-3,818	-20,009	-10,939	-7,119	-24,891	-24,891	-16,069	-11,202	-5,283	-29,687	-21,176	-19,100	-14
Income Tax Expense	0	6,252	6,286	5,975	13,699	5,583	4,590	10,193	3,458	3,276	3,324	3,216	2,187	3,116	3,054	2,475	2,734	2,388	1,873	-140	1,490	1,344	1,330	1,290	3,285	775	635	600	615	594	521	454	452	438	1,163	403	-552	346	374	220	183	158	52	92	-1,317	486	379	-618	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Interest Expense	6,215	6,398	6,299	6,115	5,737	5,580	4,573	3,389	3,316	3,299	3,247	3,196	3,109	3,091	3,067	2,717	2,731	2,649	2,073	1,541	1,438	1,402	1,359	1,323	1,242	783	642	619	628	606	538	467	464	449	453	476	381	335	343	227	168	163	159	129	42	0	3	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Interest Income	612	423	414	167	2	7	2	33	2	4	6	22	19	1	19	248	182	282	210	1,413	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Income	-17,645	2,565	-6,371	-12,764	-25,931	-20,482	-18,355	-35,201	-16,649	-17,713	-18,905	-18,380	-19,408	-16,917	-20,178	-19,245	-10,561	-11,438	-13,212	-13,068	-18,038	-15,135	-14,748	-17,822	-12,983	-15,203	-9,036	-6,537	-4,559	-4,331	-6,012	-4,612	-4,583	-5,102	-4,679	-3,606	-3,563	-3,385	-3,961	-5,904	-4,701	-2,689	-4,895	-3,242	-2,252	-3,246	-1,207	-597	-8	-5	-12	-5	-5	-5	-8	-5	-4	-3,818	-20,009	-10,939	-7,119	-24,891	-24,891	-16,069	-11,202	-5,283	-29,687	-21,176	-19,100	-14
Net Income Applicable To Common Shares	0	0	-6,371	-6,789	-12,232	-14,900	-13,765	-25,008	-16,649	-17,713	-18,905	-18,380	-19,408	-16,917	-20,178	-19,245	-10,561	-11,438	-13,212	-13,068	-18,038	-15,135	-14,748	-17,822	-12,983	-15,203	-9,036	-6,537	-4,559	-4,331	-6,012	-4,612	-4,583	-5,102	-4,679	-3,606	-3,563	-3,385	-3,961	-5,904	-4,701	-2,689	-4,895	-3,242	0	-3,246	-1,207	-597	-8	-5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Income From Continuing Ops	-17,645	2,565	-6,371	-6,789	-12,232	-14,900	-13,765	-25,008	-16,649	-17,713	-18,905	-18,380	-19,408	-16,917	-20,178	-19,245	-10,561	-11,438	-13,212	-13,068	-18,038	-15,135	-14,748	-17,822	-12,983	-15,203	-9,036	-6,537	-4,559	-4,331	-6,012	-4,612	-4,583	-5,102	-4,679	-3,606	-3,563	-3,385	-3,961	-5,904	-4,701	-2,689	-4,895	-3,242	0	-3,246	-1,207	-597	-8	-5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Interest Income	-5,602	-5,974	-5,885	-5,949	-5,735	-5,573	-4,571	-3,356	-3,313	-3,294	-3,241	-3,174	-3,090	-3,090	-3,048	-2,469	-2,549	-2,368	-1,863	-1,413	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Operating Income Net Other	0	0	401	140	-436	-2	-17	-6,804	-143	23	-77	-20	922	-25	13	242	-3	261	199	1,681	-52	58	29	34	-1,198	8	8	19	13	12	17	14	12	11	-709	73	-25	-11	-31	7	-15	5	107	37	0	0	3	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	845	30,434	-7,609	845	845	0	0	0	845	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Operating Income	14,233	8,685	-473	-813	-6,059	-9,317	-9,175	-14,815	-13,191	-14,437	-15,581	-15,164	-17,220	-13,801	-17,124	-16,770	-7,827	-9,050	-11,339	-13,208	-16,548	-13,791	-13,417	-16,533	-10,543	-14,428	-8,402	-5,937	-3,944	-3,737	-5,491	-4,159	-4,131	-4,664	-3,517	-3,202	-3,709	-3,038	-3,587	-5,684	-4,518	-2,531	-4,843	-3,150	-2,240	-3,249	-1,207	-1,214	-8	-5	-12	-5	-5	-5	-8	-5	-4	-3,818	-20,009	-10,939	-7,119	-24,891	-24,891	-16,069	-11,202	-5,283	-29,687	-21,176	-19,100	-14
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Operating Expenses	59,670	58,589	60,596	57,727	56,040	50,407	43,080	43,918	39,574	35,118	33,412	31,213	31,176	24,077	24,911	26,970	19,864	16,273	17,900	16,737	20,604	18,022	18,074	20,575	21,701	19,157	11,801	8,566	7,272	6,675	7,763	6,282	6,643	6,517	4,827	4,705	5,198	4,404	5,088	7,245	4,942	3,638	5,586	3,943	4,091	3,120	1,057	756	8	5	12	5	5	5	8	5	4	3,819	20,009	10,949	7,127	24,916	24,916	16,092	11,222	5	29,735	2	2	13
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Reconciled Depreciation	2,109	2,093	2,098	179	3,661	1,862	1,724	1,590	1,518	1,422	1,326	1,230	1,233	1,035	886	789	829	818	806	805	924	847	846	830	1,461	836	277	118	118	117	116	118	117	118	118	117	97	54	49	48	52	55	61	44	41	49	46	46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Research Development	445	596	1,403	855	1,074	1,042	873	624	729	771	1,159	988	1,013	1,708	1,656	1,529	465	491	517	871	145	1,317	1,472	1,282	1,864	1,814	1,358	1,193	583	1,677	3,400	2,028	1,997	2,112	1,506	1,402	1,920	1,483	1,784	4,330	2,956	1,409	3,470	1,468	1,268	1,941	179	82	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	16,088	11,218	0	0	0	0	-
Selling General Administrative	15,535	14,726	15,581	16,292	18,982	17,753	15,892	17,674	1,975	13,873	10,438	18,003	18,003	9,116	8,703	7,932	7,032	7,197	6,086	5,595	7,135	5,356	5,007	5,005	5,184	4,195	4,436	4,277	3,284	1,779	1,724	1,708	1,884	2,078	1,437	1,346	1,112	1,035	1,542	1,135	999	845	1,090	1,431	696	1,035	737	675	4	4	15	4	4	4	10	4	4	0	0	0	0	0	0	4	4	4	0	2	2	13
Tax Provision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Operating Expenses	16,666	15,967	17,163	17,326	20,236	18,973	16,944	18,477	16,703	14,822	14,579	13,443	12,065	12,222	11,416	10,140	8,172	8,357	7,408	7,332	9,462	8,858	8,428	8,332	9,778	7,866	7,467	6,950	5,257	4,939	6,418	5,016	5,140	5,404	4,040	3,796	4,241	3,537	4,147	6,268	4,660	2,912	5,101	3,414	3,711	2,975	916	756	8	5	12	5	5	5	8	5	4	3,819	-20,009	10,949	7,127	24,916	24,916	16,092	11,222	5	29,735	2	2	13
Total Other Income Expense Net	-31,878	-146	-13	-5,975	-6,173	-5,583	-4,590	-10,193	-145	19	-83	-42	903	-26	-6	-6	-185	-21	-10	1,554	-113	-17	-4	7	2,597	-1,583	-1,600	-1,479	-615	-1,483	4	-1,280	-452	-1,214	-719	68	-30	-15	-35	5	-17	3	104	37	1,317	-486	-379	-461	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Revenue	73,904	67,275	60,123	56,914	49,981	41,090	33,905	29,103	26,383	20,681	17,831	16,049	13,956	10,276	7,788	10,200	12,037	7,223	6,561	3,529	4,056	4,230	4,657	4,042	12,003	4,729	3,399	2,629	3,328	2,938	2,272	2,124	2,512	1,852	1,310	1,503	1,489	1,366	1,500	1,561	424	1,107	743	793	523	360	230	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	258,215
Cost of Revenue	-169,997
Gross Profit	88,218	88,218

Operating Income (+$)
Gross Profit	88,218
Operating Expense	-66,586
Operating Income	21,632	21,632

Operating Expense (+$)
Research Development	3,300
Selling General Administrative	57,380
Selling And Marketing Expenses	0
Operating Expense	66,586	60,680

Net Interest Income (+$)
Interest Income	1,007
Interest Expense	-25,027
Other Finance Cost	-478
Net Interest Income	-23,542

Pretax Income (+$)
Operating Income	21,632
Net Interest Income	-23,542
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	-28,239	71,503 EBIT - interestExpense = -3,395 -28,239 -3,212
Interest Expense	25,027
Earnings Before Interest and Taxes (EBIT)	21,632	-3,212
Earnings Before Interest and Taxes (EBITDA)	29,964

After tax Income (+$)
Income Before Tax	-28,239
Tax Provision	-0
Net Income From Continuing Ops	-22,826	-28,239
Net Income	-28,239
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	236,583
Total Other Income/Expenses Net	-49,871	23,542

Technical Analysis of ADMA Biologics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of ADMA Biologics Inc. The general trend of ADMA Biologics Inc is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine ADMA Biologics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (85.7%)		Bearish trend (-85.7%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of ADMA Biologics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.76.

The bearish price targets are: 5.895 > 5.88 > 5.1.

Tweet this

ADMA Biologics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ADMA Biologics Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

MA 20 trending down: The MA 20 is trending down. -1
Close > MA 20: The price is above the MA 20. +1
MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
MA 50 trending up: The MA 50 is trending up. +1
Close > MA 50: The price is above the MA 50. +1
MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
MA 100 trending up: The MA 100 is trending up. +1
Close > MA 100: The price is above the MA 100. +1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending up: The MA 200 is trending up. +1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

ADMA Biologics Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ADMA Biologics Inc. The current macd is 0.0760478.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the ADMA Biologics Inc price going up in the near term. +2
MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for ADMA Biologics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the ADMA Biologics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1

ADMA Biologics Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of ADMA Biologics Inc. The current adx is 19.83.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy ADMA Biologics Inc shares, leading to potential upward momentum in its price. +1
PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1

ADMA Biologics Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ADMA Biologics Inc. The current sar is 5.96803696.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1

ADMA Biologics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ADMA Biologics Inc. The current rsi is 58.00. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Trending down: The RSI is trending down. -1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

ADMA Biologics Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ADMA Biologics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the ADMA Biologics Inc price going up in the near term. +2
Trending down: The STOCH %K is trending down. -1

ADMA Biologics Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ADMA Biologics Inc. The current cci is 74.46.

ADMA Biologics Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ADMA Biologics Inc. The current cmo is 19.36.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1

ADMA Biologics Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of ADMA Biologics Inc. The current willr is -23.1292517.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that ADMA Biologics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.

ADMA Biologics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of ADMA Biologics Inc.

ADMA Biologics Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ADMA Biologics Inc. The current atr is 0.23973163.

ADMA Biologics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ADMA Biologics Inc. The current obv is 91,786,596.

ADMA Biologics Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ADMA Biologics Inc. The current mfi is 62.43.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

MFI > 50: +1

ADMA Biologics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for ADMA Biologics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-12-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2023-12-06	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-07	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2023-12-08	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2023-12-11	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-13	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-14	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-15	STOCH	LONG EXIT		The %K line crosses below the %D line.
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-19	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-27	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-01-03	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-01-05	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-01-09	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-10	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-11	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-01-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-16	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-17	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-01-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-01-19	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-01-22	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-23	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-24	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-01-25	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
2024-01-29	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-30	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-01-31	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-08	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-02-09	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-12	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-13	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-14	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-15	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-16	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-20	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-21	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-22	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-26	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-27	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-02-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-03-04	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-03-06	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-03-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-11	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-13	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-14	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-03-15	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-03-18	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
2024-03-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-03-20	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-03-21	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-25	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-03-26	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-03-27	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-03-28	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-03	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-04-04	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-09	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-10	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-04-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-16	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-17	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-04-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-04-19	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
2024-04-23	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-04-24	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.

6.3. Candlestick Patterns

ADMA Biologics Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of ADMA Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	58.000
Ma 20	Greater than	Ma 50	6.290
Ma 50	Greater than	Ma 100	5.993
Ma 100	Greater than	Ma 200	5.309
Open	Greater than	Close	6.540
Total			5/5 (100.0%)

Create your own Symbol Scanner

Get notifications about ADMA Biologics Inc

I send you an email if I find something interesting about ADMA Biologics Inc.

ADMA Biologics Inc Buy, Hold or Sell?

Let's analyse ADMA Biologics Inc together

Get notifications about ADMA Biologics Inc

Quick analysis of ADMA Biologics Inc (30 sec.)

What can you expect buying and holding a share of ADMA Biologics Inc? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of ADMA Biologics Inc (5 min.)

$6.46

$0.59

$-0.98 - $10.72

$-0.39 - $11.32

2. Growth of ADMA Biologics Inc (5 min.)

Is ADMA Biologics Inc growing?

How much money is ADMA Biologics Inc making?

How much money comes from the company's main activities?

3. Financial Health of ADMA Biologics Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of ADMA Biologics Inc? (5 min.)

What can you expect buying and holding a share of ADMA Biologics Inc?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of ADMA Biologics Inc

About ADMA Biologics Inc

Financial Health

Valuation

1.1. Profitability of ADMA Biologics Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of ADMA Biologics Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of ADMA Biologics Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of ADMA Biologics Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of ADMA Biologics Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

ADMA Biologics Inc
Buy, Hold or Sell?